APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 5
MAY 2005



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2005

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

Cumulative Supplement 5

May 2005

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

CUMULATIVE SUPPLEMENT 5
May 2005

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS	UCB PHARMA INC (UCB)
FUJISAWA HEALTHCARE	ASTELLAS PHARMA US INC

(FUJISAWA HLTHCARE)	(ASTELLAS)
SHIRE LABORATORIES INC	SHIRE DEVELOPMENT INC
(SHIRE LABS)	(SHIRE)
SHIRE PHARMACEUTICAL DEVELOPMENT INC	SHIRE DEVELOPMENT INC
(SHIRE PHARM)	(SHIRE)
YAMANOUCHI PHARMA AMERICA INC	ASTELLAS PHARMA US INC
(YAMANOUCHI)	(ASTELLAS)

1.3 LEVOTHYROXINE SODIUM

The Description of Special Situations, Levothyroxine Sodium, published in the 25th Annual Edition of the Orange Book, has been modified in the Cumulative Supplement to include information on Genpharm ANDA 76752 approved in 2005. The full discussion as published in the 25th Annual Edition is repeated in the Cumulative Supplement and includes recent approval information on levothyroxine sodium.

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Genpharm ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma NDA 021301) tablets.

Novothyrox (Genpharm NDA 021292) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Thyro-Tabs (Lloyd NDA 021116) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Levolet (Vintage NDA 021137) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	JONES PHARMA	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	GENPHARM	0.025MG	AB2	76752	001
LEVOXYL	JONES PHARMA	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
NOVOTHYROX	GENPHARM	0.025MG	BX	21292	001
THYRO-TABS	LLOYD	0.025MG	BX	21116	001
LEVOLET	VINTAGE PHARMS	0.025MG	BX	21137	001

1.4 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB http://www.fda.gov/cder/ob/default.htm, has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at http://www.fda.gov/cder/ob/default.htm. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

The Internet version of the Orange Book annual edition is at http://www.fda.gov/cder/ob/docs/preface/ectablec.htm The Internet version of the monthly supplement is at http://www.fda.gov/cder/orange/supplement/cspreface.htm_.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm . The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2004	MAR 2005	JUN 2005	SEP 2005
DRUG PRODUCTS LISTED	11082	11184		
SINGLE SOURCE	2427 (21.9%)	2437 (21.8%)		
MULTISOURCE	8547 (77.1%)	8637 (77.2%)		
THERAPEUTICALLY EQUIVALENT	8327 (75.1%)	8428 (75.4%)		
NOT THERAPEUTICALLY EQUIVALENT	220 (2.0%)	209 (1.9%)		
EXCEPTIONS[1]	108 (1.0%)	110 (1.0%)		
NEW MOLECULAR ENTITIES APPROVED	9	2		
NUMBER OF APPLICANTS	625	631		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>D>	AB	ABLE	325MG;50MG;40MG	N40390	001	Jul 23, 2001	May	DISC
>A>		@	325MG;50MG;40MG	N40390	001	Jul 23, 2001	May	DISC
>D>	AB		500MG;50MG;40MG	N40394	001	Jul 23, 2001	May	DISC
>A>		@	500MG;50MG;40MG	N40394	001	Jul 23, 2001	May	DISC

BUTALBITAL, APAP, AND CAFFEINE

	AB	WATSON LABS	325MG;50MG;40MG	N89536	001	Feb 16, 1988	Feb	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; CAFFEINE AND CODEINE PHOSPHATE

>D>	AB	ABLE	325MG;50MG;40MG;30MG	N76528	001	Aug 21, 2003	May	DISC
>A>		@	325MG;50MG;40MG;30MG	N76528	001	Aug 21, 2003	May	DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D>	AA	ABLE	300MG;30MG	N40452	001	Aug 01, 2002	May	DISC
>A>		@	300MG;30MG	N40452	001	Aug 01, 2002	May	DISC
>D>	AA		300MG;60MG	N40459	001	Aug 01, 2002	May	DISC
>A>		@	300MG;60MG	N40459	001	Aug 01, 2002	May	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>	AA	ABLE	325MG;5MG	N40478	001	Nov 08, 2002	May	DISC
>A>		@	325MG;5MG	N40478	001	Nov 08, 2002	May	DISC
>D>	AA		325MG;7.5MG	N40464	001	Oct 23, 2002	May	DISC
>A>		@	325MG;7.5MG	N40464	001	Oct 23, 2002	May	DISC
>D>	AA		325MG;10MG	N40464	002	Oct 23, 2002	May	DISC
>A>		@	325MG;10MG	N40464	002	Oct 23, 2002	May	DISC
>D>	AA		500MG;5MG	N40477	001	Nov 06, 2002	May	DISC
>A>		@	500MG;5MG	N40477	001	Nov 06, 2002	May	DISC
>D>	AA		500MG;7.5MG	N40490	001	May 21, 2003	May	DISC
>A>		@	500MG;7.5MG	N40490	001	May 21, 2003	May	DISC
>D>	AA		500MG;10MG	N40473	001	Nov 06, 2002	May	DISC
>A>		@	500MG;10MG	N40473	001	Nov 06, 2002	May	DISC
>D>	AA		650MG;7.5MG	N40474	001	Jan 02, 2003	May	DISC
>A>		@	650MG;7.5MG	N40474	001	Jan 02, 2003	May	DISC
>D>	AA		650MG;10MG	N40476	001	Oct 23, 2002	May	DISC
>A>		@	650MG;10MG	N40476	001	Oct 23, 2002	May	DISC
>D>	AA		750MG;7.5MG	N40469	001	Oct 25, 2002	May	DISC
>A>		@	750MG;7.5MG	N40469	001	Oct 25, 2002	May	DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>D>	AB	ABLE	650MG;100MG	N75838	001	Jul 11, 2001	May	DISC
>A>		@	650MG;100MG	N75838	001	Jul 11, 2001	May	DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND TRAMADOL HCL

AB		KALI LABS	325MG;37.5MG	N76475	001	Apr 21, 2005	Mar	NEWA

ULTRACET

AB	+	ORTHO MCNEIL PHARM	325MG;37.5MG	N21123	001	Aug 15, 2001	Mar	CFTG

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

AT	+	MORTON GROVE	2%	N40166	001	Jul 26, 1996	Jan	CRLD
AT		VINTAGE	2%	N40607	001	Feb 24, 2005	Feb	NEWA

VOSOL

	@	MEDPOINTE PHARM HLC	2%	N12179	001		Jan	DISC

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

MUCOSIL-10

>D>								
>D>	AN	DEY	10%	N70575	001	Oct 14, 1986	May	DISC
>A>		@	10%	N70575	001	Oct 14, 1986	May	DISC

MUCOSIL-20

>D>								
>D>	AN	DEY	20%	N70576	001	Oct 14, 1986	May	DISC
>A>		@	20%	N70576	001	Oct 14, 1986	May	DISC

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

	+	UCB	8MG;60MG	N19806	001	Mar 25, 1994	Mar	CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB		TEVA PHARMS	200MG	N74914	001	Nov 26, 1997	Mar	CAHN

SUSPENSION; ORAL

ACYCLOVIR

>A>	AB	HI TECH PHARMA	200MG/5ML	N77026	001	Jun 07, 2005	May	NEWA

TABLET; ORAL

ACYCLOVIR

AB		TEVA PHARMS	400MG	N75021	001	Mar 18, 1998	Mar	CAHN
AB			800MG	N75021	002	Mar 18, 1998	Mar	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

	@	ABBOTT	EQ 50MG BASE/ML	N75114	001	Jul 26, 1999	Feb	DISC

ADENOSINE

INJECTABLE; INJECTION

ADENSOINE

AP		AM PHARM	3MG/ML	N77133	001	Apr 27, 2005	Apr	NEWA

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	+	DEY	EQ 0.083% BASE	N72652	001	Feb 21, 1992	Jan	CRLD

TABLET; ORAL
ALBUTEROL SULFATE

AB	+	MYLAN	EQ 2MG BASE	N72894	002	Jan 17, 1991	Apr	CMS1

ALENDRONATE SODIUM

SOLUTION; ORAL
FOSAMAX

	+	MERCK	EQ 70MG BASE/75ML	N21575	001	Sep 17, 2003	Apr	CPOT

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL
FOSAMAX PLUS D

	+	MERCK	EQ 70MG BASE;2,800 IU	N21762	001	Apr 07, 2005	Apr	NEWA

ALPRAZOLAM

TABLET, ORALLY DISINTEGRATING; ORAL
NIRAVAM

		SCHWARZ PHARMA	0.25MG	N21726	001	Jan 19, 2005	Jan	NEWA
			0.5MG	N21726	002	Jan 19, 2005	Jan	NEWA
			1MG	N21726	003	Jan 19, 2005	Jan	NEWA
	+		2MG	N21726	004	Jan 19, 2005	Jan	NEWA

ALPROSTADIL

INJECTABLE; INJECTION
EDEX

AP	+	SCHWARZ PHARMA	0.01MG/VIAL	N20649	005	Jul 30, 1998	Apr	CTEC
AP	+		0.02MG/VIAL	N20649	006	Jul 30, 1998	Apr	CTEC
AP	+		0.04MG/VIAL	N20649	007	Jul 30, 1998	Apr	CTEC

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL

AA		TEVA PHARMS	50MG/5ML	N73115	001	Aug 23, 1991	Mar	CAHN

AMINO ACIDS

INJECTABLE; INJECTION

>D>		AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE						
>D>		HOSPIRA	5.2% (5.2GM/100ML)	N18901	001	Apr 06, 1984	May	DISC
>A>		@	5.2% (5.2GM/100ML)	N18901	001	Apr 06, 1984	May	DISC
		AMINOSYN 7%						
		HOSPIRA	7% (7GM/100ML)	N17673	002		Mar	CMFD
		AMINOSYN 8.5%						
		HOSPIRA	8.5% (8.5GM/100ML)	N17673	004		Mar	CMFD

AMIODARONE

INJECTABLE; INTRAVENOUS
AMIODARONE HCL

AP		APOTEX	50MG/ML	N77161	001	Apr 20, 2005	Mar	NEWA

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HCL

AP	+	AM PHARM PARTNERS	50MG/ML	N75761	001	Oct 15, 2002	Mar	CRLD
AP	+	APOTEX	50MG/ML	N76394	001	Apr 25, 2003	Mar	CRLD
AP	+	BEDFORD	50MG/ML	N76018	001	Oct 15, 2002	Mar	CRLD
AP	+	BEDFORD LABS	50MG/ML	N76299	001	Oct 24, 2002	Mar	CRLD

INJECTABLE; INJECTION
AMIODARONE HCL

AP	+	BEN VENUE	50MG/ML	N76088	001	Oct 15, 2002	Mar	CRLD
AP	+	BIONICHE (CANADA)	50MG/ML	N76217	001	Oct 15, 2002	Mar	CRLD
AP	+	MAYNE PHARMA USA	50MG/ML	N76108	001	Oct 15, 2002	Mar	CRLD
AP	+	SICOR PHARMS	50MG/ML	N76163	001	Sep 05, 2003	Mar	CRLD

TABLET; ORAL
AMIODARONE HCL

AB		AUROSAL PHARMS	200MG	N77069	001	Apr 08, 2005	Mar	NEWA
AB			400MG	N77069	002	Apr 08, 2005	Mar	NEWA
AB		TARO	100MG	N75424	002	Dec 18, 2002	Mar	CTEC
AB		TEVA PHARMS	200MG	N74739	001	Nov 30, 1998	Mar	CAHN

PACERONE

AB		UPSHER SMITH	100MG	N75135	002	Apr 12, 2005	Mar	NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL
TRIMOX

AB		APOTHECON	50MG/ML	N61886	001		Apr	CMFD
AB			125MG/5ML	N61886	002		Apr	CMFD
AB			250MG/5ML	N61886	003		Apr	CMFD

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		HIKMA PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	N65191	002	Jan 25, 2005	Jan	NEWA
AB			400MG/5ML;EQ 57MG BASE/5ML	N65191	001	Jan 25, 2005	Jan	NEWA

TABLET, CHEWABLE; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		TEVA	200MG;EQ 28.5MG BASE	N65205	001	Feb 09, 2005	Jan	NEWA
AB			400MG;EQ 57MG BASE	N65205	002	Feb 09, 2005	Jan	NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC

>D>	+	INTERMUNE PHARMS	50MG/VIAL	N50729	001	Nov 22, 1996	May	CAHN
>D>	+		100MG/VIAL	N50729	002	Nov 22, 1996	May	CAHN
>A>	+	THREE RIVERS PHARMS	50MG/VIAL	N50729	001	Nov 22, 1996	May	CAHN
>A>	+		100MG/VIAL	N50729	002	Nov 22, 1996	May	CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

AP		INSTITUTO BIOCHEMICO	EQ 125MG BASE/VIAL	N62797	001	Jul 12, 1993	Jan	CMFD
AP			EQ 2GM BASE/VIAL	N62797	002	Jul 12, 1993	Jan	CAHN

AMPRENAVIR

CAPSULE; ORAL
AGENERASE

>D>		GLAXOSMITHKLINE	50MG	N21007	001	Apr 15, 1999	May	CRLD
>A>	+		50MG	N21007	001	Apr 15, 1999	May	CRLD
>D>	+		150MG	N21007	002	Apr 15, 1999	May	DISC
>A>	@		150MG	N21007	002	Apr 15, 1999	May	DISC

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB		SHIRE	EQ 0.5MG BASE	N20333	001	Mar 14, 1997	Mar	CFTG
AB	+		EQ 1MG BASE	N20333	002	Mar 14, 1997	Mar	CFTG

ANAGRELIDE HCL

AB		BARR	EQ 0.5MG BASE	N76530	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76530	002	Apr 18, 2005	Mar	NEWA
AB		EON	EQ 0.5MG BASE	N76683	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76683	002	Apr 18, 2005	Mar	NEWA
AB		IMPAX LABS	EQ 0.5MG BASE	N76910	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76910	002	Apr 18, 2005	Mar	NEWA
AB		IVAX PHARMS	EQ 0.5MG BASE	N76468	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76468	002	Apr 18, 2005	Mar	NEWA
AB		MYLAN	EQ 0.5MG BASE	N76811	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76811	002	Apr 18, 2005	Mar	NEWA
AB		ROXANE	EQ 0.5MG BASE	N76489	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76489	002	Apr 18, 2005	Mar	NEWA
AB		WATSON LABS	EQ 0.5MG BASE	N76417	001	Apr 18, 2005	Mar	NEWA
AB			EQ 1MG BASE	N76417	002	Apr 18, 2005	Mar	NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL W/ ASPIRIN & CAFFEINE

>D>	AB	PHARMERAL	325MG;50MG;40MG	N87048	002	Dec 09, 1983	May	DISC
>A>		@	325MG;50MG;40MG	N87048	002	Dec 09, 1983	May	DISC

BUTALBITAL, ASPIRIN AND CAFFEINE

>D>	AB	WEST WARD	325MG;50MG;40MG	N86162	002	Feb 16, 1984	May	CRLD
>A>	AB	+	325MG;50MG;40MG	N86162	002	Feb 16, 1984	May	CRLD

FIORINAL

>D>	AB	+ WATSON PHARMS	325MG;50MG;40MG	N17534	003	Apr 16, 1986	May	DISC
>A>		@	325MG;50MG;40MG	N17534	003	Apr 16, 1986	May	DISC

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

>D>		+ CENT PHARMS	500MG;5MG	N89420	001	Jan 25, 1988	May	CAHN
>A>		+ SCHWARZ PHARMA	500MG;5MG	N89420	001	Jan 25, 1988	May	CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

>D>	AB	ABLE	25MG	N76907	001	Jul 30, 2004	May	DISC
>A>		@	25MG	N76907	001	Jul 30, 2004	May	DISC
>D>	AB		50MG	N76907	002	Jul 30, 2004	May	DISC
>A>		@	50MG	N76907	002	Jul 30, 2004	May	DISC
>D>	AB		100MG	N76907	003	Jul 30, 2004	May	DISC
>A>		@	100MG	N76907	003	Jul 30, 2004	May	DISC
	AB	MYLAN	25MG	N73457	002	Apr 26, 1999	Mar	CTEC
	AB	TEVA PHARMS	50MG	N74120	001	Feb 24, 1995	Mar	CAHN
	AB		100MG	N74120	002	Feb 24, 1995	Mar	CAHN
	AB	ZYDUS PHARMS USA	25MG	N76900	001	Jan 28, 2005	Jan	NEWA
	AB		50MG	N76900	002	Jan 28, 2005	Jan	NEWA
	AB		100MG	N76900	003	Jan 28, 2005	Jan	NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL
STRATTERA

		LILLY	80MG	N21411	007	Feb 14, 2005	Feb	NEWA
			100MG	N21411	008	Feb 14, 2005	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

>D>	AA	ABLE	0.025MG;2.5MG	N40395	001	Nov 27, 2000	May	DISC
>A>		@	0.025MG;2.5MG	N40395	001	Nov 27, 2000	May	DISC

AZELAIC ACID

GEL; TOPICAL
FINACEA

>D>		+ BERLEX	15%	N21470	001	Dec 24, 2002	May	CAHN
>A>		+ INTENDIS	15%	N21470	001	Dec 24, 2002	May	CAHN

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION
VANCERIL

		@ SCHERING	0.042MG/INH	N17573	001		Apr	DISC

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

		@ HOLLISTER STIER LABS	60UMOLAR	N50114	001		Mar	DISC

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE

	AB	TEVA PHARMS	EQ 0.05% BASE	N71882	001	Jun 06, 1988	Mar	CAHN

OINTMENT; TOPICAL
ALPHATREX

		@ SAVAGE LABS	EQ 0.05% BASE	N19143	001	Sep 04, 1984	Jan	DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

>A>	AB	ALTANA PHARMA	EQ 0.05% BASE;1%	N76516	001	Jun 16, 2005	May	NEWA

BETAMETHASONE VALERATE

LOTION; TOPICAL
BETAMETHASONE VALERATE

	AB	TEVA PHARMS	EQ 0.1% BASE	N71883	001	Apr 22, 1988	Mar	CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

>D>	AA	ABLE	5MG	N40492	001	Jul 27, 2004	May	DISC
>A>		@	5MG	N40492	001	Jul 27, 2004	May	DISC
>D>	AA		10MG	N40483	001	Jul 27, 2004	May	DISC
>A>		@	10MG	N40483	001	Jul 27, 2004	May	DISC
>D>	AA		25MG	N40485	001	Jul 27, 2004	May	DISC
>A>		@	25MG	N40485	001	Jul 27, 2004	May	DISC

TABLET; ORAL
BETHANECHOL CHLORIDE

>D>	AA	ABLE	50MG	N40509	001	Jul 27, 2004	May	DISC
>A>		@	50MG	N40509	001	Jul 27, 2004	May	DISC
>A>	AA	UPSHER SMITH	5MG	N40633	001	Jun 01, 2005	May	NEWA
>A>	AA		10MG	N40634	001	Jun 01, 2005	May	NEWA
>A>	AA		25MG	N40635	001	Jun 01, 2005	May	NEWA
>A>	AA		50MG	N40636	001	Jun 01, 2005	May	NEWA

DUVOID

	AA	WELLSPRING PHARM	50MG	N85882	003		Apr	CMFD

BISOPROLOL FUMARATE

TABLET; ORAL
BISOPROLOL FUMARATE

	AB	TEVA PHARMS	5MG	N75644	001	Jun 26, 2001	Mar	CAHN
	AB		10MG	N75644	002	Jun 26, 2001	Mar	CAHN

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
XIBROM

	+	ISTA PHARMS	0.09%	N21664	001	Mar 24, 2005	Mar	NEWA

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL
BROMOCRIPTINE MESYLATE

	AB	MYLAN	EQ 5MG BASE	N77226	001	Apr 04, 2005	Mar	NEWA

PARLODEL

	AB +	NOVARTIS	EQ 5MG BASE	N17962	002	Mar 01, 1982	Mar	CTEC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL
BROMFED-DM

>A>	AA	BRIGHTON PHARMS INC	2MG/5ML;10MG/5ML;30MG/5ML	N89681	001	Dec 22, 1988	May	CAHN
>D>	AA	VERUM PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	N89681	001	Dec 22, 1988	May	CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPRENORPHINE HCL

	AP	BEDFORD	EQ 0.3MG BASE/ML	N76931	001	Mar 02, 2005	Feb	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
BUPROPION HCL

>A>	AB1	EON	200MG	N75932	003	Jun 22, 2005	May	NEWA

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL
MENTAX

	+	MYLAN BERTEK	1%	N20524	001	Oct 18, 1996	Apr	CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
MIGERGOT

	BR	G AND W LABS	100MG;2MG	N86557	001	Oct 04, 1983	Feb	CMFD

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	TEVA PHARMS	12.5MG	N74462	001	Feb 13, 1996	Mar	CAHN
AB		25MG	N74462	002	Feb 13, 1996	Mar	CAHN
AB		50MG	N74462	003	Feb 13, 1996	Mar	CAHN
AB		100MG	N74462	004	Feb 13, 1996	Mar	CAHN

CARBAMAZEPINE

SUSPENSION; ORAL
CARBAMAZEPINE

@ TARO	100MG/5ML	N75875	001	Dec 21, 2000	Mar	DISC

CARBIDOPA; LEVODOPA

TABLET, FOR SUSPENSION; ORAL
CARBILEV

>A>	RANBAXY	10MG;100MG	N76643	001	Jun 10, 2005	May	NEWA
>A>		25MG;100MG	N76643	002	Jun 10, 2005	May	NEWA
>A>	+	25MG;250MG	N76643	003	Jun 10, 2005	May	NEWA

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN

AP	EON	50MG/VIAL	N76959	001	Mar 18, 2005	Mar	NEWA
AP		150MG/VIAL	N76959	002	Mar 18, 2005	Mar	NEWA
AP		450MG/VIAL	N76959	003	Mar 18, 2005	Mar	NEWA

INJECTABLE; IV (INFUSION)
CARBOPLATIN

>A>	AP	SPECTRUM PHARMS	EQ 50MG/5ML(10MG/ML)	N77096	001	Jun 14, 2005	May	NEWA
>A>	AP		EQ 150MG/15ML(10MG/ML)	N77096	002	Jun 14, 2005	May	NEWA
>A>	AP		EQ 450MG/45ML(10MG/ML)	N77096	003	Jun 14, 2005	May	NEWA

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

>D>	AA	ABLE	350MG	N40421	001	Jun 21, 2001	May	DISC
>A>		@	350MG	N40421	001	Jun 21, 2001	May	DISC
>A>	AA	NEIL	350MG	N40576	001	Jun 07, 2005	May	NEWA

CEFACLOR

CAPSULE; ORAL
CECLOR

@ LILLY	EQ 250MG BASE	N50521	001		Mar	DISC
@	EQ 500MG BASE	N50521	002		Mar	DISC

CEFACLOR

AB	+	RANBAXY	EQ 500MG BASE	N64156	002	Aug 28, 1997	Mar	CRLD

FOR SUSPENSION; ORAL
CECLOR

AB	CEPH INTL	EQ 375MG BASE/5ML	N62206	004	Apr 20, 1988	Mar	CRLD
@ LILLY	EQ 125MG BASE/5ML	N50522	001		Mar	DISC
@	EQ 250MG BASE/5ML	N50522	002		Mar	DISC

CEFACLOR

AB	CEPH INTL	EQ 125MG BASE/5ML	N62206	001		Apr	CTNA
AB		EQ 187MG BASE/5ML	N62206	003	Apr 20, 1988	Apr	CTNA
AB		EQ 250MG BASE/5ML	N62206	002		Apr	CTNA

FOR SUSPENSION; ORAL
CEFACLOR

AB		CEPH INTL	EQ 375MG BASE/5ML	N62206	004	Apr 20, 1988	Apr	CTNA
AB	+	RANBAXY	EQ 375MG BASE/5ML	N64155	001	Oct 02, 1997	Mar	CRLD

CEFADROXIL/CEFADROXIL HEMIHYDRATE

TABLET; ORAL
CEFADROXIL

AB		IVAX PHARMS	EQ 1GM BASE	N62774	001	Apr 08, 1987	Apr	CMFD

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	+	AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N64169	001	Aug 14, 1998	Mar	CRLD
AP	+		EQ 1GM BASE/VIAL	N64169	002	Aug 14, 1998	Mar	CRLD
AP	+		EQ 10GM BASE/VIAL	N64170	001	Mar 18, 1998	Mar	CRLD
AP		ORCHID HLTHCARE	EQ 500MG BASE/VIAL	N65226	001	Apr 21, 2005	Apr	NEWA
AP			EQ 1GM BASE/VIAL	N65226	002	Apr 21, 2005	Apr	NEWA

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE

AP		SANDOZ	EQ 250MG BASE/VIAL	N65169	001	May 09, 2005	Apr	NEWA
AP			EQ 500MG BASE/VIAL	N65169	002	May 09, 2005	Apr	NEWA
AP			EQ 1GM BASE/VIAL	N65169	003	May 09, 2005	Apr	NEWA
AP			EQ 2GM BASE/VIAL	N65169	004	May 09, 2005	Apr	NEWA

INJECTABLE; INJECTION
CEFTRIAXONE

AP		SANDOZ	EQ 1GM BASE/VIAL	N65204	001	May 03, 2005	Apr	NEWA
AP			EQ 2GM BASE/VIAL	N65204	002	May 03, 2005	Apr	NEWA
AP			EQ 10GM BASE/VIAL	N65168	001	May 17, 2005	Apr	NEWA

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

AP	+	B BRAUN	EQ 1GM BASE/VIAL	N50796	001	Apr 20, 2005	Apr	NEWA
AP	+		EQ 2GM BASE/VIAL	N50796	002	Apr 20, 2005	Apr	NEWA

ROCEPHIN

	@	HLR	EQ 250MG BASE/VIAL	N63239	001	Aug 13, 1993	Apr	DISC
	@		EQ 500MG BASE/VIAL	N63239	002	Aug 13, 1993	Apr	DISC
	+		EQ 1GM BASE/VIAL	N62654	002	Apr 30, 1987	Mar	CRLD
AP	+		EQ 1GM BASE/VIAL	N62654	002	Apr 30, 1987	Apr	CFTG
	@		EQ 1GM BASE/VIAL	N63239	003	Aug 13, 1993	Apr	DISC
AP	+		EQ 2GM BASE/VIAL	N62654	003	Apr 30, 1987	Apr	CFTG
AP	+		EQ 10GM BASE/VIAL	N50585	005	Dec 21, 1984	Apr	CFTG

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

AP	+	B BRAUN	EQ 750MG BASE/VIAL	N50780	001	Feb 21, 2001	Apr	CPOT
AP	+		EQ 1.5GM BASE/VIAL	N50780	002	Feb 21, 2001	Apr	CPOT

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

	@	APOTHECON	EQ 250MG BASE	N63186	001	Dec 30, 1994	Mar	DISC
	@		EQ 500MG BASE	N63186	002	Dec 30, 1994	Mar	DISC
AB		BELCHER	EQ 250MG BASE	N62713	001	Jul 15, 1988	Jan	CAHN
AB			EQ 500MG BASE	N62713	002	Jul 15, 1988	Jan	CAHN

CAPSULE; ORAL
CEPHALEXIN

AB		SUN PHARM INDS (IN)	EQ 250MG BASE	N62791	001	Jun 11, 1987	Jan	CAHN
AB			EQ 500MG BASE	N62791	002	Jun 11, 1987	Jan	CAHN
AB		YUNG SHIN PHARM	EQ 250MG BASE	N65152	001	Feb 24, 2005	Feb	NEWA
AB			EQ 500MG BASE	N65152	002	Feb 24, 2005	Feb	NEWA

CHLOROTHIAZIDE

SUSPENSION; ORAL
DIURIL

>D>		@ MERCK	250MG/5ML	N11870	001		May	CMFD
>A>		+	250MG/5ML	N11870	001		May	CMFD

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
CODEPREX

		+ UCB	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369	001	Jun 21, 2004	Mar	CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
TUSSIONEX

		+ UCB	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	N19111	001	Dec 31, 1987	Mar	CAHN

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL
CHLORPROMAZINE HCL

>D>	BP	+ SANDOZ	10MG	N80439	001		May	CRLD
>A>	BP		10MG	N80439	001		May	CRLD
	BP	+	10MG	N80439	001		Apr	CRLD
	BP	+	100MG	N80439	004		Apr	CRLD

THORAZINE

		@ GLAXOSMITHKLINE	10MG	N09149	002		Apr	DISC
		@	25MG	N09149	007		Apr	DISC
		@	50MG	N09149	013		Apr	DISC
		@	100MG	N09149	018		Apr	DISC
		@	200MG	N09149	020		Apr	DISC

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE

AB		TEVA PHARMS	EQ 4GM RESIN/SCOOPFUL	N74554	002	Oct 02, 1996	Mar	CAHN
AB			EQ 4GM RESIN/PACKET	N74554	001	Oct 02, 1996	Mar	CAHN

CHOLESTYRAMINE LIGHT

AB		TEVA PHARMS	EQ 4GM RESIN/SCOOPFUL	N74555	002	Sep 30, 1998	Mar	CAHN
AB			EQ 4GM RESIN/PACKET	N74555	001	Sep 30, 1998	Mar	CAHN

CICLOPIROX

CREAM; TOPICAL
CICLOPIROX

AB		TARO	0.77%	N76790	001	Apr 12, 2005	Mar	NEWA

CILOSTAZOL

TABLET; ORAL
CILOSTAZOL

AB		COREPHARMA	50MG	N77150	001	Mar 11, 2005	Feb	NEWA

TABLET; ORAL
CILOSTAZOL

AB	IVAX PHARMS	100MG	N77020	002	Mar 01, 2005	Feb		NEWA
AB	ROXANE	50MG	N77024	001	May 17, 2005	Apr		NEWA
AB		100MG	N77024	002	May 17, 2005	Apr		NEWA

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

>D> AP	LUITPOLD	EQ 300MG BASE/2ML	N74353	001	Dec 20, 1994	May		DISC
>A>	@	EQ 300MG BASE/2ML	N74353	001	Dec 20, 1994	May		DISC

CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> AP	HOSPIRA	EQ 6MG BASE/ML	N74269	001	Dec 27, 1994	May		CRLD
>A> +		EQ 6MG BASE/ML	N74269	001	Dec 27, 1994	May		CRLD

>D> TAGAMET

>D> AP +	GLAXOSMITHKLINE	EQ 300MG BASE/2ML	N17939	002		May		DISC
>A>	@	EQ 300MG BASE/2ML	N17939	002		May		DISC

>D> TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> AP +	GLAXOSMITHKLINE	EQ 6MG BASE/ML	N19434	001	Oct 31, 1985	May		DISC
>A>	@	EQ 6MG BASE/ML	N19434	001	Oct 31, 1985	May		DISC

SOLUTION; ORAL
CIMETIDINE HCL

AA	TEVA PHARMS	EQ 300MG BASE/5ML	N74859	001	Jul 09, 1998	Mar		CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN

AT	HITECH PHARMA	EQ 0.3% BASE	N76673	001	Jan 21, 2005	Jan		NEWA

>A> TABLET, EXTENDED RELEASE; ORAL
>A> PROQUIN XR

>A> +	DEPOMED INC	EQ 500MG BASE	N21744	001	May 19, 2005	May		NEWA

TABLET; ORAL
CIPROFLOXACIN

AB	COBALT	EQ 100MG BASE	N76794	001	Feb 10, 2005	Jan		NEWA
>A> AB	PLIVA	EQ 100MG BASE	N76426	001	Jun 15, 2005	May		NEWA
>A> AB		EQ 250MG BASE	N76426	002	Jun 15, 2005	May		NEWA
>A> AB		EQ 500MG BASE	N76426	003	Jun 15, 2005	May		NEWA
>A> AB		EQ 750MG BASE	N76426	004	Jun 15, 2005	May		NEWA
AB	SANDOZ	EQ 100MG BASE	N75939	001	Mar 03, 2005	Feb		NEWA
AB	TARO	EQ 100MG BASE	N76912	001	Feb 18, 2005	Jan		NEWA

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

AB	AKYMA PHARMS	EQ 10MG BASE	N77045	003	Apr 29, 2005	Apr		NEWA
AB		EQ 20MG BASE	N77045	002	Apr 29, 2005	Apr		NEWA
AB		EQ 40MG BASE	N77045	001	Apr 29, 2005	Apr		NEWA
AB	MYLAN	EQ 10MG BASE	N77039	001	Feb 03, 2005	Jan		NEWA
AB		EQ 20MG BASE	N77039	002	Feb 03, 2005	Jan		NEWA
AB		EQ 40MG BASE	N77039	003	Feb 03, 2005	Jan		NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL
CLARITHROMYCIN

	RANBAXY	1GM	N65210	001	Jan 26, 2005	Jan		NEWA
AB	TEVA	500MG	N65154	001	May 18, 2005	Apr		NEWA

TABLET; ORAL
CLARITHROMYCIN

	AB	GENPHARM	250MG	N65195	001	Mar 11, 2005	Feb	NEWA
	AB		500MG	N65195	002	Mar 11, 2005	Feb	NEWA
>A>	AB	IVAX PHARMS	250MG	N65137	001	May 31, 2005	May	NEWA
>A>	AB		500MG	N65137	002	May 31, 2005	May	NEWA
>A>	AB	TEVA	250MG	N65155	001	May 31, 2005	May	NEWA
>A>	AB		500MG	N65155	002	May 31, 2005	May	NEWA

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

	AA	TEVA PHARMS	EQ 0.5MG BASE/5ML	N73095	001	Apr 21, 1992	Mar	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HYDROCHLORIDE

	AB	ZYDUS PHARMS USA	EQ 75MG BASE	N65217	001	Jan 31, 2005	Jan	NEWA
	AB		EQ 150MG BASE	N65217	002	Jan 31, 2005	Jan	NEWA
	AB		EQ 300MG BASE	N65217	003	Jan 31, 2005	Jan	NEWA

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

	AP	HOSPIRA	EQ 150MG BASE/ML	N62943	001	Sep 29, 1988	Mar	CMFD
>D>		CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	+ BAXTER HLTHCARE	EQ 6MG BASE/ML	N50648	001	Dec 29, 1989	May	DISC
>A>		@	EQ 6MG BASE/ML	N50648	001	Dec 29, 1989	May	DISC
>D>	AP	+	EQ 12MG BASE/ML	N50648	002	Dec 29, 1989	May	DISC
>A>		@	EQ 12MG BASE/ML	N50648	002	Dec 29, 1989	May	DISC
>D>	AP	+	EQ 900MG BASE/100ML	N50648	003	Dec 29, 1989	May	DISC
>A>		@	EQ 900MG BASE/100ML	N50648	003	Dec 29, 1989	May	DISC

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE

	AB1	TEVA PHARMS	0.05%	N74087	001	Feb 16, 1994	Mar	CAHN

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

	AB	TEVA PHARMS	0.05%	N74089	001	Feb 16, 1994	Mar	CAHN

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM

	AB	KALI LABS	0.5MG	N77147	001	May 02, 2005	Apr	NEWA
	AB		1MG	N77147	002	May 02, 2005	Apr	NEWA
	AB		2MG	N77147	003	May 02, 2005	Apr	NEWA

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

>D>	AB	ABLE	3.75MG	N71780	001	Jun 26, 1987	May	DISC
>A>		@	3.75MG	N71780	001	Jun 26, 1987	May	DISC
>D>	AB		7.5MG	N71781	001	Jun 26, 1987	May	DISC
>A>		@	7.5MG	N71781	001	Jun 26, 1987	May	DISC
>D>	AB		15MG	N71782	001	Jun 26, 1987	May	DISC

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM
>A> @ ABLE 15MG N71782 001 Jun 26, 1987 May DISC

CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE
\+ TARO 1% N72640 001 Aug 31, 1993 Feb CRLD
LOTRIMIN
@ SCHERING PLOUGH 1% N17619 001 Feb DISC
MYCELEX
@ BAYER PHARMS 1% N18183 001 Feb DISC

CLOZAPINE

TABLET; ORAL
CLOZAPINE
IVAX PHARMS 50MG N74949 004 Apr 25, 2005 Apr NEWA
AB TEVA 25MG N75162 001 Apr 26, 2005 Apr NEWA
AB 100MG N75162 002 Apr 26, 2005 Apr NEWA

CROMOLYN SODIUM

SOLUTION, CONCENTRATE; ORAL
GASTROCROM
\+ UCB 100MG/5ML N20479 001 Feb 29, 1996 Mar CAHN
SOLUTION; INHALATION
CROMOLYN SODIUM
>A> AN BREATH LTD 10MG/ML N76469 001 Jun 17, 2005 May NEWA

CYANOCOBALAMIN

SPRAY, METERED; NASAL
NASCOBAL
\+ NASTECH PHARM 0.5MG/SPRAY N21642 001 Jan 31, 2005 Jan NEWA
\+ QUESTCOR PHARMS 0.5MG/SPRAY N21642 001 Jan 31, 2005 Feb CAHN

CYCLOSPORINE

CAPSULE; ORAL
CYCLOSPORINE
AB1 IVAX PHARMS 25MG N65110 003 Mar 29, 2005 Mar NEWA
AB1 50MG N65110 001 Mar 29, 2005 Mar NEWA
AB1 100MG N65110 002 Mar 29, 2005 Mar NEWA
GENGRAF
AB1 ABBOTT 50MG N65003 002 May 12, 2000 Mar CTEC
SOLUTION; ORAL
CYCLOSPORINE
AB1 IVAX PHARMS 100MG/ML N65078 001 Mar 25, 2005 Mar NEWA

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL
@ ABC HOLDING 4MG N88212 001 May 26, 1983 Feb DISC

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN
\+ PHARMACIA AND UPJOHN 7,500 IU/0.3ML N20287 005 Apr 04, 2002 Jan NEWA
@ 7,500 IU/0.75ML N20287 008 Apr 04, 2002 Apr DISC

INJECTABLE; INJECTION
FRAGMIN
\+ PHARMACIA AND UPJOHN 95,000IU/9.5ML(10,000IU/ML) N20287 007 Apr 04, 2002 Apr NEWA
\+ 95,000IU/3.8ML(25,000IU/ML) N20287 006 Apr 04, 2002 Apr NEWA

DANTROLENE SODIUM

CAPSULE; ORAL
DANTRIUM
AB PROCTER AND GAMBLE 25MG N17443 001 Feb CFTG
AB 50MG N17443 003 Feb CFTG
AB \+ 100MG N17443 002 Feb CFTG
DANTROLENE SODIUM
AB IMPAX LABS 25MG N76856 001 Mar 01, 2005 Feb NEWA
AB 50MG N76856 002 Mar 01, 2005 Feb NEWA
AB 100MG N76856 003 Mar 01, 2005 Feb NEWA

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS
IPRIVASK
\+ CANYON 15MG/VIAL N21271 001 Apr 04, 2003 Mar CAIN

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARINEX D 24 HOUR
\+ SCHERING 5MG;240MG N21605 001 Mar 03, 2005 Mar NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)
AB APOTEX 0.01MG/SPRAY N76703 001 Jan 27, 2005 Jan NEWA

DESONIDE

CREAM; TOPICAL
DESONIDE
AB TEVA PHARMS 0.05% N74027 001 Sep 28, 1992 Mar CAHN

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE
PAR PHARM 0.25MG N88149 001 Apr 28, 1983 Mar CRLD
BP ROXANE 1.5MG N84610 001 Mar CRLD

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE
AP AM PHARM EQ 10MG PHOSPHATE/ML N40572 001 Apr 22, 2005 Apr NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

>A> CAPSULE, EXTENDED RELEASE; ORAL
>A> FOCALIN XR
>A> NOVARTIS 5MG N21802 001 May 26, 2005 May NEWA
>A> 10MG N21802 002 May 26, 2005 May NEWA
>A> \+ 20MG N21802 003 May 26, 2005 May NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

>D>	AB		ABLE	5MG	N76814	001	Aug 25, 2004	May	DISC
>A>		@		5MG	N76814	001	Aug 25, 2004	May	DISC
>D>	AB			10MG	N76814	002	Aug 25, 2004	May	DISC
>A>		@		10MG	N76814	002	Aug 25, 2004	May	DISC
>D>	AB			15MG	N76814	003	Aug 25, 2004	May	DISC
>A>		@		15MG	N76814	003	Aug 25, 2004	May	DISC

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 50% IN PLASTIC CONTAINER

	AP		HOSPIRA	500MG/ML	N19445	001	Jun 03, 1986	Mar	CMFD

DIAZEPAM

GEL; RECTAL

DIASTAT

			VALEANT	2.5MG/0.5ML	N20648	001	Jul 29, 1997	Apr	CAHN
				5MG/ML	N20648	002	Jul 29, 1997	Apr	CAHN
				10MG/2ML	N20648	003	Jul 29, 1997	Apr	CAHN
				15MG/3ML	N20648	004	Jul 29, 1997	Apr	CAHN
		+		20MG/4ML	N20648	005	Jul 29, 1997	Apr	CAHN

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

	AB		TEVA PHARMS	25MG	N74459	001	Jun 25, 1997	Mar	CAHN
	AB			50MG	N74459	002	Jun 25, 1997	Mar	CAHN
	AB			75MG	N74459	003	Jun 25, 1997	Mar	CAHN

VOLTAREN

>D>	AB	+	NOVARTIS	25MG	N19201	001	Jul 28, 1988	May	DISC
>A>		@		25MG	N19201	001	Jul 28, 1988	May	DISC
>D>	AB	+		50MG	N19201	002	Jul 28, 1988	May	DISC
>A>		@		50MG	N19201	002	Jul 28, 1988	May	DISC

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

>D>		+	GD SEARLE LLC	50MG;0.2MG	N20607	001	Dec 24, 1997	May	CRLD
>A>				50MG;0.2MG	N20607	001	Dec 24, 1997	May	CRLD

DICYCLOMINE HYDROCHLORIDE

SYRUP; ORAL

BENTYL

	AA	+	AXCAN SCANDIPHARM	10MG/5ML	N07961	002	Oct 15, 1984	Mar	CTEC

DICYCLOMINE HCL

	AA		MIKART	10MG/5ML	N40169	001	Mar 24, 2005	Mar	NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HCL

			@ ABC HOLDING	25MG	N88267	001	Aug 25, 1983	Feb	DISC
			@	25MG	N88268	001	Aug 25, 1983	Feb	DISC

TABLET; ORAL
TENUATE
+ AVENTIS PHARMS 25MG N11722 002 Feb CTEC

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION
D.H.E. 45
AP + VALEANT 1MG/ML N05929 001 Apr CAHN

SPRAY, METERED; NASAL
MIGRANAL
+ VALEANT 0.5MG/INH N20148 001 Dec 08, 1997 Apr CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM CD
>D> AB3 + BIOVAIL 120MG N20062 001 Aug 10, 1992 May CRLD
>A> AB3 120MG N20062 001 Aug 10, 1992 May CRLD
>D> AB3 + 180MG N20062 002 Dec 27, 1991 May CRLD
>A> AB3 180MG N20062 002 Dec 27, 1991 May CRLD
>D> AB3 + 240MG N20062 003 Dec 27, 1991 May CRLD
>A> AB3 240MG N20062 003 Dec 27, 1991 May CRLD
>D> AB3 + 300MG N20062 004 Dec 27, 1991 May CRLD
>A> AB3 300MG N20062 004 Dec 27, 1991 May CRLD
DILACOR XR
>D> AB2 + WATSON LABS 120MG N20092 001 May 29, 1992 May CRLD
>A> AB2 120MG N20092 001 May 29, 1992 May CRLD
>D> AB2 + 180MG N20092 002 May 29, 1992 May CRLD
>A> AB2 180MG N20092 002 May 29, 1992 May CRLD
DILTIAZEM HCL
>D> + MYLAN 60MG N74910 001 May 02, 1997 May CRLD
>A> 60MG N74910 001 May 02, 1997 May CRLD
>D> + 90MG N74910 002 May 02, 1997 May CRLD
>A> 90MG N74910 002 May 02, 1997 May CRLD

INJECTABLE; INJECTION
CARDIZEM
AP + BIOVAIL LABS INTL 5MG/ML N20027 001 Oct 24, 1991 Mar CAHN
+ 25MG/VIAL N20027 003 Aug 18, 1995 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL
CARDIZEM LA
BIOVAIL LABS INTL 120MG N21392 001 Feb 06, 2003 Mar CAHN
180MG N21392 002 Feb 06, 2003 Mar CAHN
240MG N21392 003 Feb 06, 2003 Mar CAHN
300MG N21392 004 Feb 06, 2003 Mar CAHN
360MG N21392 005 Feb 06, 2003 Mar CAHN
+ 420MG N21392 006 Feb 06, 2003 Mar CAHN

TABLET; ORAL
CARDIZEM
AB BIOVAIL LABS INTL 30MG N18602 001 Nov 05, 1982 Mar CAHN
AB 60MG N18602 002 Nov 05, 1982 Mar CAHN
AB 90MG N18602 003 Dec 08, 1986 Mar CAHN
AB + 120MG N18602 004 Dec 08, 1986 Mar CAHN
DILTIAZEM HCL
AB TEVA PHARMS 30MG N74067 001 Nov 05, 1992 Mar CAHN
AB 60MG N74067 002 Nov 05, 1992 Mar CAHN
AB 90MG N74067 003 Nov 05, 1992 Mar CAHN
AB 120MG N74067 004 Nov 05, 1992 Mar CAHN

DIPYRIDAMOLE

TABLET; ORAL
PERSANTINE

>D>	AB	+	BOEHRINGER INGELHEIM	50MG	N12836	004	Feb 06, 1987	May	CRLD
>A>	AB			50MG	N12836	004	Feb 06, 1987	May	CRLD
>D>	AB			75MG	N12836	005	Feb 06, 1987	May	CRLD
>A>	AB	+		75MG	N12836	005	Feb 06, 1987	May	CRLD

DOXAZOSIN MESYLATE

TABLET, EXTENDED RELEASE; ORAL
CARDURA XL

			PFIZER	EQ 4MG BASE	N21269	001	Feb 22, 2005	Feb	NEWA
		+		EQ 8MG BASE	N21269	002	Feb 22, 2005	Feb	NEWA

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL
DOXEPIN HCL

	AA		TEVA PHARMS	EQ 10MG BASE/ML	N71609	001	Nov 09, 1987	Mar	CAHN

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

	AB		PAR PHARM	EQ 75MG BASE	N65055	004	Apr 18, 2005	Mar	NEWA
	AB		RANBAXY	EQ 75MG BASE	N65053	003	Sep 10, 2003	Mar	CTEC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

		+	WEST WARD	EQ 20MG BASE	N65103	001	May 13, 2005	Apr	NEWA

TABLET, DELAYED RELEASE; ORAL
DORYX

>A>			FAULDING	EQ 75MG BASE	N50795	001	May 06, 2005	May	NEWA
>A>		+		EQ 100MG BASE	N50795	002	May 06, 2005	May	NEWA

TABLET; ORAL
DOXYCYCLINE HYCLATE

	AB		COREPHARMA	EQ 20MG BASE	N65182	001	May 13, 2005	Apr	NEWA
	AB		IVAX PHARMS	EQ 20MG BASE	N65163	001	May 13, 2005	Apr	NEWA
	AB		MUTUAL PHARMA	EQ 20MG BASE	N65134	001	May 13, 2005	Apr	NEWA

PERIOSTAT

	AB	+	COLLAGENEX PHARMS	EQ 20MG BASE	N50783	001	Feb 02, 2001	Apr	CFTG

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

			@ APOTHECON	2.5MG	N75583	001	Aug 22, 2000	Feb	DISC
			@	5MG	N75583	002	Aug 22, 2000	Feb	DISC
			@	10MG	N75583	003	Aug 22, 2000	Feb	DISC
			@	20MG	N75583	004	Aug 22, 2000	Feb	DISC

VASOTEC

	AB		BIOVAIL LABS INTL	2.5MG	N18998	005	Jul 26, 1988	Mar	CAHN
	AB			5MG	N18998	001	Dec 24, 1985	Mar	CAHN
	AB			10MG	N18998	002	Dec 24, 1985	Mar	CAHN
	AB	+		20MG	N18998	003	Dec 24, 1985	Mar	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
VASERETIC

AB		BIOVAIL LABS INTL	5MG;12.5MG	N19221	003	Jul 12, 1995	Mar	CAHN
AB	+		10MG;25MG	N19221	001	Oct 31, 1986	Mar	CAHN

ENALAPRILAT

INJECTABLE; INJECTION
VASOTEC

AP	+	BIOVAIL LABS INTL	1.25MG/ML	N19309	001	Feb 09, 1988	Mar	CAHN

ENTECAVIR

SOLUTION; ORAL
BARACLUDE

	+	BRISTOL MYERS SQUIBB	0.05MG/ML	N21798	001	Mar 29, 2005	Mar	NEWA

TABLET; ORAL
BARACLUDE

		BRISTOL MYERS SQUIBB	0.5MG	N21797	001	Mar 29, 2005	Mar	NEWA
	+		1MG	N21797	002	Mar 29, 2005	Mar	NEWA

EPINEPHRINE

INJECTABLE; IM-SC
TWINJECT 0.30

	+	HOLLISTER STIER LABS	EQ 0.3MG /DELIVERY	N20800	001	May 30, 2003	Feb	CTNA

EPROSARTAN MESYLATE

TABLET; ORAL
TEVETEN

>D>		BIOVAIL	EQ 300MG BASE	N20738	004	Dec 22, 1997	May	CAHN
>D>			EQ 400MG BASE	N20738	005	Dec 22, 1997	May	CAHN
>D>	+		EQ 600MG BASE	N20738	006	May 27, 1999	May	CAHN
>A>		KOS LIFE	EQ 300MG BASE	N20738	004	Dec 22, 1997	May	CAHN
>A>			EQ 400MG BASE	N20738	005	Dec 22, 1997	May	CAHN
>A>	+		EQ 600MG BASE	N20738	006	May 27, 1999	May	CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
TEVETEN HCT

>D>		BIOVAIL	600MG;12.5MG	N21268	001	Nov 01, 2001	May	CAHN
>D>	+		600MG;25MG	N21268	002	Nov 01, 2001	May	CAHN
>A>		KOS LIFE	600MG;12.5MG	N21268	001	Nov 01, 2001	May	CAHN
>A>	+		600MG;25MG	N21268	002	Nov 01, 2001	May	CAHN

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYMAX

AT		MERZ PHARMS	2%	N62508	002	Jul 11, 1985	Jan	CAHN

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE

		@ BARR	EQ 250MG BASE	N62162	002		Feb	DISC

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

ESMOLOL HCL

AP		AM PHARM	10MG/ML	N76573	001	May 02, 2005	Apr NEWA
AP		PHARMAFORCE	10MG/ML	N76474	001	May 02, 2005	Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

NEXIUM

		ASTRAZENECA	EQ 20MG BASE	N21153	001	Feb 20, 2001	Jan CRLD

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

NEXIUM IV

	+	ASTRAZENECA	20MG/VIAL	N21689	001	Mar 31, 2005	Mar NEWA
	+		40MG/VIAL	N21689	002	Mar 31, 2005	Mar NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

AB2	+	BERLEX	0.025MG/24HR	N20375	004	Mar 05, 1999	Jan CFTG
AB2	+		0.075MG/24HR	N20375	003	Mar 23, 1998	Jan CFTG

ESCLIM

	@	WOMEN FIRST HLTHCARE	0.025MG/24HR	N20847	001	Aug 04, 1998	Jan DISC
	@		0.0375MG/24HR	N20847	002	Aug 04, 1998	Jan DISC
	@		0.05MG/24HR	N20847	003	Aug 04, 1998	Jan DISC
	@		0.075MG/24HR	N20847	004	Aug 04, 1998	Jan DISC
	@		0.1MG/24HR	N20847	005	Aug 04, 1998	Jan DISC

ESTRADIOL

AB2		MYLAN TECHNOLOGIES	0.025MG/24HR	N75182	003	Jan 26, 2005	Jan NEWA
AB2			0.075MG/24HR	N75182	002	Jan 26, 2005	Jan NEWA

VIVELLE

	@	NOVARTIS	0.025MG/24HR	N20323	005	Aug 16, 2000	Jan DISC
AB1			0.05MG/24HR	N20323	002	Oct 28, 1994	Jan CRLD
AB1			0.1MG/24HR	N20323	004	Oct 28, 1994	Jan CRLD

VIVELLE-DOT

BX	+	NOVARTIS	0.025MG/24HR	N20538	009	May 03, 2002	Jan CRLD
BX	+		0.0375MG/24HR	N20538	005	Jan 08, 1999	Jan CRLD
AB1	+		0.05MG/24HR	N20538	006	Jan 08, 1999	Jan CRLD
BX	+		0.075MG/24HR	N20538	007	Jan 08, 1999	Jan CRLD
AB1	+		0.1MG/24HR	N20538	008	Jan 08, 1999	Jan CRLD

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATE

AB		BARR	1MG,1MG;N/A,0.09MG	N76812	001	Apr 29, 2005	Apr NEWA

PREFEST

AB	+	DURAMED	1MG,1MG;N/A,0.09MG	N21040	001	Oct 22, 1999	Apr CFTG

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

	@	DURAMED	0.3MG	N21443	001	Dec 20, 2004	Mar DISC
	@		0.45MG	N21443	002	Dec 20, 2004	Mar DISC

ESTROPIPATE

TABLET; ORAL

ORTHO-EST

>A>	AB	SUN PHARM INDS (IN)	0.75MG	N89567	001	Feb 27, 1991	May	CAHN
>A>	AB		1.5MG	N89582	001	Jul 17, 1991	May	CAHN
>D>	AB	WOMEN FIRST HLTHCARE	0.75MG	N89567	001	Feb 27, 1991	May	CAHN
>D>	AB		1.5MG	N89582	001	Jul 17, 1991	May	CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

>A> KELNOR

>A>	AB	BARR	0.035MG;1MG	N76785	001	May 23, 2005	May	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

>D>	AB	BARR	0.035MG;0.4MG	N76198	001	Apr 22, 2004	May	CRLD
>A>	+		0.035MG;0.4MG	N76198	001	Apr 22, 2004	May	CRLD

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

	+	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041	001	Sep 24, 1991	Mar	CTEC

NORTREL 7/7/7

		BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N75478	001	Aug 30, 2002	Mar	CTEC

>D> OVCON-35

>D>	AB	+ WARNER CHILCOTT	0.035MG;0.4MG	N18127	001		May	DISC
>A>		@	0.035MG;0.4MG	N18127	001		May	DISC

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

		WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71042	001	Sep 24, 1991	Mar	CTEC

ORTHO-NOVUM 10/11-28

	AB	+ ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N18354	002	Jan 11, 1982	Mar	CRLD

ORTHO-NOVUM 7/14-28

		@ ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N19004	002	Apr 04, 1984	Feb	DISC

OVCON-35

	AB	WARNER CHILCOTT	0.035MG;0.4MG	N17716	001		Mar	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>A>	AB	ANDRX PHARMS	0.02MG;1MG	N77077	001	May 20, 2005	May	NEWA
	AB		0.03MG;1.5MG	N77075	001	Apr 28, 2005	Apr	NEWA

ETHOSUXIMIDE

SYRUP; ORAL

ETHOSUXIMIDE

	AA	TEVA PHARMS	250MG/5ML	N81306	001	Jul 30, 1993	Mar	CAHN

ETODOLAC

CAPSULE; ORAL

LODINE

>D>	AB	WYETH PHARMS INC	200MG	N18922	002	Jan 31, 1991	May	DISC
>A>		@	200MG	N18922	002	Jan 31, 1991	May	DISC

TABLET, EXTENDED RELEASE; ORAL

>D> LODINE XL

>D>	AB	WYETH PHARMS INC	400MG	N20584	001	Oct 25, 1996	May	DISC
>A>		@	400MG	N20584	001	Oct 25, 1996	May	DISC

TABLET, EXTENDED RELEASE; ORAL
LODINE XL
>D> AB + WYETH PHARMS INC 500MG N20584 003 Jan 20, 1998 May DISC
>A> @ 500MG N20584 003 Jan 20, 1998 May DISC

TABLET; ORAL
LODINE
>D> AB WYETH PHARMS INC 400MG N18922 004 Jul 29, 1993 May DISC
>A> @ 400MG N18922 004 Jul 29, 1993 May DISC
>D> AB + 500MG N18922 005 Jun 28, 1996 May DISC
>A> @ 500MG N18922 005 Jun 28, 1996 May DISC

EXENATIDE SYNTHETIC

INJECTABLE; SUBCUTANEOUS
BYETTA
+ AMYLIN 300UGM/1.2ML(250UGM/ML) N21773 001 Apr 28, 2005 Apr NEWA
+ 600UGM/2.4ML(250UGM/ML) N21773 002 Apr 28, 2005 Apr NEWA

FENOFIBRATE

TABLET; ORAL
FENOFIBRATE
AB TEVA 54MG N76433 001 May 13, 2005 Apr NEWA
AB 160MG N76433 002 May 13, 2005 Apr NEWA
TRICOR
AB ABBOTT 54MG N21203 001 Sep 04, 2001 Apr CFTG
AB + 160MG N21203 003 Sep 04, 2001 Apr CFTG
>A> TRIGLIDE
>A> SKYEPHARMA 50MG N21350 001 May 07, 2005 May NEWA
>A> BX 160MG N21350 002 May 07, 2005 May NEWA

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
FENOLDOPAM MESYLATE
AP SABEX 2002 EQ 10MG BASE/ML N77155 001 Feb 15, 2005 Jan NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL
NALFON
AB + PEDINOL EQ 300MG BASE N17604 002 Apr CAHN
NALFON 200
AB PEDINOL EQ 200MG BASE N17604 003 Apr CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC-100
AB ALZA 100UGM/HR N19813 001 Aug 07, 1990 Jan CFTG
DURAGESIC-12
ALZA 12.5UGM/HR N19813 005 Feb 04, 2005 Feb NEWA
DURAGESIC-25
AB + ALZA 25UGM/HR N19813 004 Aug 07, 1990 Jan CFTG
DURAGESIC-50
AB ALZA 50UGM/HR N19813 003 Aug 07, 1990 Jan CFTG
DURAGESIC-75
AB ALZA 75UGM/HR N19813 002 Aug 07, 1990 Jan CFTG
FENTANYL
AB MYLAN TECHNOLOGIES 25UGM/HR N76258 001 Jan 28, 2005 Jan NEWA
AB 50UGM/HR N76258 002 Jan 28, 2005 Jan NEWA
AB 75UGM/HR N76258 003 Jan 28, 2005 Jan NEWA

FILM, EXTENDED RELEASE; TRANSDERMAL
FENTANYL

AB		MYLAN TECHNOLOGIES	100UGM/HR	N76258	004	Jan 28, 2005	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALLEGRA-D 12 HOUR

AB	+	AVENTIS PHARMS	60MG;120MG	N20786	001	Dec 24, 1997	Mar	CFTG

FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCL

AB		BARR	60MG;120MG	N76236	001	Apr 14, 2005	Mar	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		APOTEX	200MG/100ML	N76888	001	Mar 25, 2005	Mar	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		APOTEX	200MG/100ML	N76889	001	Mar 25, 2005	Mar	NEWA

FLUCYTOSINE

CAPSULE; ORAL
ANCOBON

		VALEANT	250MG	N17001	001		Apr	CAHN
	+		500MG	N17001	002		Apr	CAHN

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL

AP		SABEX 2002	0.5MG/5ML (0.1MG/ML)	N77071	001	May 03, 2005	Apr	NEWA
AP			1MG/10ML (0.1MG/ML)	N77071	002	May 03, 2005	Apr	NEWA

FLUOCINOLONE ACETONIDE

IMPLANT; INTRAVITREAL
RETISERT

	+	BAUSCH AND LOMB	0.59MG	N21737	001	Apr 08, 2005	Apr	NEWA

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL
TRI-LUMA

>A>	+	GALDERMA LABS LP	0.01%;4%;0.05%	N21112	001	Jan 18, 2002	May	CAHN
>D>	+	HILL DERMAC	0.01%;4%;0.05%	N21112	001	Jan 18, 2002	May	CAHN

FLUOCINONIDE

CREAM; TOPICAL
VANOS

	+	MEDICIS	0.1%	N21758	001	Feb 11, 2005	Feb	NEWA

SOLUTION; TOPICAL
FLUOCINONIDE

AT		TEVA PHARMS	0.05%	N72522	001	Sep 28, 1990	Mar	CAHN

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

AP	+	VALEANT	50MG/ML	N12209	001		Apr	CAHN

>D>		FLUOXETINE						
>D>		CAPSULE; ORAL						
>D>		FLUOXETINE						
>D>	AB	RANBAXY	40MG	N76990	001	Dec 13, 2004	May	CAIN
		FLUOXETINE HYDROCHLORIDE						
		CAPSULE; ORAL						
		FLUOXETINE						
	AB	BARR	EQ 40MG BASE	N76251	001	May 18, 2005	Apr	NEWA
>A>	AB	RANBAXY	EQ 40MG BASE	N76990	001	Dec 13, 2004	May	CAIN
		FLUPHENAZINE HYDROCHLORIDE						
		CONCENTRATE; ORAL						
		FLUPHENAZINE HCL						
	AA	TEVA PHARMS	5MG/ML	N73058	001	Aug 30, 1991	Mar	CAHN
		ELIXIR; ORAL						
		FLUPHENAZINE HCL						
	AA	TEVA PHARMS	2.5MG/5ML	N81310	001	Apr 29, 1993	Mar	CAHN
		FLUTICASONE PROPIONATE						
		AEROSOL, METERED; INHALATION						
		FLOVENT						
	+	GLAXOSMITHKLINE	0.044MG/INH	N20548	001	Mar 27, 1996	Jan	CRLD
	+		0.11MG/INH	N20548	002	Mar 27, 1996	Jan	CRLD
		FLOVENT HFA						
	+	GLAXOSMITHKLINE	0.044MG/INH	N21433	003	May 14, 2004	Jan	CRLD
	+		0.11MG/INH	N21433	002	May 14, 2004	Jan	CRLD
		LOTION; TOPICAL						
		CUTIVATE						
	+	GLAXOSMITHKLINE	0.05%	N21152	001	Mar 31, 2005	Mar	NEWA
		OINTMENT; TOPICAL						
		FLUTICASONE PROPIONATE						
>A>	AB	TARO PHARM INDS	0.005%	N77145	001	Jun 14, 2005	May	NEWA
		FOLIC ACID						
		TABLET; ORAL						
		FOLIC ACID						
>A>	AA	TRIGEN	1MG	N40514	001	Jun 14, 2005	May	NEWA
		FOLLITROPIN ALFA/BETA						
		INJECTABLE; SUBCUTANEOUS						
		FOLLISTIM AQ						
	+	ORGANON USA INC	150 IU/0.18ML	N21211	003	Feb 11, 2004	Feb	NEWA
	+		300 IU/0.36ML	N21211	001	Mar 23, 2004	Jan	CPOT
	+		600 IU/0.72ML	N21211	002	Mar 23, 2004	Jan	CPOT
	+		900 IU/1.08ML	N21211	004	Feb 11, 2005	Feb	NEWA
		FOMIVIRSEN SODIUM						
		INJECTABLE; INJECTION						
		VITRAVENE PRESERVATIVE FREE						
	@	NOVARTIS	6.6MG/ML	N20961	001	Aug 26, 1998	Feb	DISC

FOSCARNET SODIUM

INJECTABLE; INJECTION

>A>		FOSCARNET SODIUM						
>A>	AP	PHARMAFORCE	2.4GM/100ML	N77174	001	May 31, 2005	May	NEWA
		FOSCAVIR						
>D>	+	ASTRAZENECA	2.4GM/100ML	N20068	001	Sep 27, 1991	May	CFTG
>A>	AP	+	2.4GM/100ML	N20068	001	Sep 27, 1991	May	CFTG

FOSINOPRIL SODIUM

TABLET; ORAL

		FOSINOPRIL SODIUM						
AB		APOTEX	10MG	N76906	001	May 17, 2005	Apr	NEWA
AB			20MG	N76906	002	May 17, 2005	Apr	NEWA
AB			40MG	N76906	003	May 17, 2005	Apr	NEWA
AB		INVAGEN PHARMS	10MG	N77222	001	Apr 20, 2005	Mar	NEWA
AB			20MG	N77222	002	Apr 20, 2005	Mar	NEWA
AB			40MG	N77222	003	Apr 20, 2005	Mar	NEWA

FUROSEMIDE

INJECTABLE; INJECTION

		FUROSEMIDE						
AP	+	LUITPOLD	10MG/ML	N18579	001	Nov 30, 1983	Feb	CRLD
		LASIX						
		@ AVENTIS PHARMS	10MG/ML	N16363	001		Feb	DISC

GABAPENTIN

CAPSULE; ORAL

		GABAPENTIN						
AB		APOTEX	100MG	N75360	001	Apr 06, 2005	Mar	NEWA
AB			300MG	N75360	002	Apr 06, 2005	Mar	NEWA
AB			400MG	N75360	003	Apr 06, 2005	Mar	NEWA
AB		EON	100MG	N75539	001	Apr 06, 2005	Mar	NEWA
AB			300MG	N75539	002	Apr 06, 2005	Mar	NEWA
AB			400MG	N75539	003	Apr 06, 2005	Mar	NEWA
AB		IVAX PHARMS	100MG	N75477	001	Mar 23, 2005	Mar	NEWA
AB			300MG	N75477	002	Mar 23, 2005	Mar	NEWA
AB			400MG	N75477	003	Mar 23, 2005	Mar	NEWA

TABLET; ORAL

		GABAPENTIN						
AB		IVAX PHARMS	600MG	N76017	004	Apr 29, 2005	Apr	NEWA
AB			800MG	N76017	005	Apr 29, 2005	Apr	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

		REMINYL						
	+	JOHNSON AND JOHNSON	EQ 8MG BASE	N21615	001	Dec 22, 2004	Jan	CRLD
			EQ 24MG BASE	N21615	003	Dec 22, 2004	Jan	CRLD

GATIFLOXACIN

INJECTABLE; INJECTION

		TEQUIN						
	+	BRISTOL MYERS SQUIBB	400MG/40ML(10MG/ML)	N21062	004	Dec 17, 1999	Mar	CPOT
		TEQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
	+	BRISTOL MYERS SQUIBB	200MG/100ML(2MG/ML)	N21062	001	Dec 17, 1999	Mar	CPOT
	+		400MG/200ML(2MG/ML)	N21062	002	Dec 17, 1999	Mar	CPOT

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

>D>			GARAMYCIN						
>D>	AT	+	SCHERING	EQ 0.3% BASE	N50039	002		May	DISC
>A>			@	EQ 0.3% BASE	N50039	002		May	DISC
			GENTAMICIN SULFATE						
>D>	AT		ALTANA	EQ 3% BASE	N65121	001	Jan 30, 2004	May	CPOT
>A>	AT			EQ 0.3% BASE	N65121	001	Jan 30, 2004	May	CPOT

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

			GLYBURIDE AND METFORMIN HCL						
AB			TEVA	1.25MG;250MG	N76821	001	Jan 27, 2005	Jan	NEWA
AB				2.5MG;500MG	N76821	002	Jan 27, 2005	Jan	NEWA
AB				5MG;500MG	N76821	003	Jan 27, 2005	Jan	NEWA

GLYCOPYRROLATE

TABLET; ORAL

			GLYCOPYRROLATE						
AA			COREPHARMA	1MG	N40568	001	Dec 22, 2004	Apr	CTEC
AA				2MG	N40568	002	Dec 22, 2004	Apr	CTEC
			ROBINUL						
AA		+	FIRST HORIZON	1MG	N12827	001		Apr	CTEC
			ROBINUL FORTE						
AA		+	FIRST HORIZON	2MG	N12827	002		Apr	CTEC

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

			CHORIONIC GONADOTROPIN						
			@ WATSON LABS (UTAH)	2,000 UNITS/VIAL	N17016	009	Dec 27, 1984	Feb	CAHN
			@	2,000 UNITS/VIAL	N17016	011	Feb 16, 1990	Feb	CAHN
			@	5,000 UNITS/VIAL	N17016	006		Feb	CAHN
AP		+		10,000 UNITS/VIAL	N17016	007		Feb	CAHN
			@	15,000 UNITS/VIAL	N17016	010	Feb 15, 1985	Feb	CAHN
			@	20,000 UNITS/VIAL	N17016	004		Feb	CAHN

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

			GRIFULVIN V						
AB		+	J AND J	125MG/5ML	N62483	001	Jan 26, 1984	Feb	CFTG
			GRISEOFULVIN						
AB			STIEFEL	125MG/5ML	N65200	001	Mar 02, 2005	Feb	NEWA

GUANABENZ ACETATE

TABLET; ORAL

			GUANABENZ ACETATE						
AB			TEVA PHARMS	EQ 4MG BASE	N74267	001	Jun 01, 1994	Mar	CAHN
AB				EQ 8MG BASE	N74267	002	Jun 01, 1994	Mar	CAHN

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

			HALOBETASOL PROPIONATE						
>A>	AB		ALPHARMA US PHARMS	0.05%	N77109	001	Jun 14, 2005	May	NEWA

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

		HALOPERIDOL							
AA	+	TEVA PHARMS	EQ 2MG BASE/ML	N71617	001	Dec 01, 1988	Mar	CAHN	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

		HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE							
AA		IVAX PHARMS	1.5MG/5ML;5MG/5ML	N40285	001	Jul 19, 1999	Jan	CAHN	

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

		HYDRALAZINE HCL							
		@ ABC HOLDING	10MG	N88846	001	Feb 26, 1985	Feb	DISC	
		@	25MG	N88847	001	Feb 26, 1985	Feb	DISC	
		@	50MG	N88848	001	Feb 26, 1985	Feb	DISC	
		@	100MG	N88849	001	Feb 26, 1985	Feb	DISC	

HYDROCHLOROTHIAZIDE

TABLET; ORAL

		HYDROCHLOROTHIAZIDE							
		@ ABC HOLDING	25MG	N85683	001		Feb	DISC	
		@	50MG	N83965	001		Feb	DISC	
		@	50MG	N85672	001		Feb	DISC	
AB	+	IVAX PHARMS	50MG	N83177	002		Apr	CRLD	
		@	100MG	N85022	001		Apr	DISC	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

		AVALIDE							
		SANOFI SYNTHELABO	12.5MG;300MG	N20758	003	Aug 31, 1998	Mar	CRLD	
	+		25MG;300MG	N20758	004	Mar 15, 2005	Mar	NEWA	

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

		INDERIDE-40/25							
>D>	AB	WYETH PHARMS INC	25MG;40MG	N18031	001		May	CRLD	
>A>	AB	+	25MG;40MG	N18031	001		May	CRLD	
>D>		INDERIDE-80/25							
>D>	AB	+ WYETH PHARMS INC	25MG;80MG	N18031	002		May	DISC	
>A>		@	25MG;80MG	N18031	002		May	DISC	

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

		QUINAPRIL HCL AND HYDROCHLOROTHIAZIDE							
AB		MYLAN	12.5MG;EQ 10MG BASE	N77093	001	Mar 28, 2005	Mar	NEWA	
AB			12.5MG;EQ 20MG BASE	N77093	002	Mar 28, 2005	Mar	NEWA	
AB			25MG;EQ 20MG BASE	N77093	003	Mar 28, 2005	Mar	NEWA	

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

		DIOVAN HCT							
		NOVARTIS	12.5MG;160MG	N20818	002	Mar 06, 1998	Mar	CRLD	
	+		25MG;160MG	N20818	003	Jan 17, 2002	Mar	CRLD	

HYDROCORTISONE

ENEMA; RECTAL

HYDROCORTISONE

	AB		TEVA PHARMS	100MG/60ML	N74171 001	May 27, 1994	Mar	CAHN

OINTMENT; TOPICAL

CORTRIL

>D>								
>D>	AT	+	PFIPHARMECS	1%	N09176 001		May	DISC
>D>	AT	+		2.5%	N09176 002		May	DISC
>A>			@ PFIZER GLOBAL	1%	N09176 001		May	DISC
>A>			@	2.5%	N09176 002		May	DISC

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

	AB		TEVA PHARMS	0.2%	N74489 001	Aug 12, 1998	Mar	CAHN

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

			PURDUE PHARMA LP	16MG	N21044 002	Sep 24, 2004	Feb	CRLD
		+		32MG	N21044 004	Sep 24, 2004	Feb	CRLD

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

	AB		TEVA PHARMS	200MG	N40081 001	Sep 30, 1994	Mar	CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

			@ WATSON LABS	125MG/ML	N17439 001		Mar	CAHN
			@	250MG/ML	N17439 002		Mar	CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HCL

>D>	AB		ABLE	10MG	N40559 001	Jul 22, 2004	May	DISC
>A>			@	10MG	N40559 001	Jul 22, 2004	May	DISC
>D>	AB			25MG	N40562 001	Jul 22, 2004	May	DISC
>A>			@	25MG	N40562 001	Jul 22, 2004	May	DISC
>D>	AB			50MG	N40563 001	Jul 22, 2004	May	DISC
>A>			@	50MG	N40563 001	Jul 22, 2004	May	DISC
>A>	AB		VINTAGE PHARMS	10MG	N40579 001	May 27, 2005	May	NEWA
>A>	AB			25MG	N40574 001	May 27, 2005	May	NEWA
>A>	AB			50MG	N40580 001	May 27, 2005	May	NEWA

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

		+	ROCHE	EQ 2.5MG BASE	N21455 001	May 16, 2003	Feb	CMFD
				EQ 150MG BASE	N21455 002	Mar 24, 2005	Mar	NEWA
		+		EQ 150MG BASE	N21455 002	Mar 24, 2005	Apr	CRLD

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HCL

		@ TEVA	10MG	N83729	001		Feb	DISC
		@	25MG	N83729	004		Feb	DISC
		@	50MG	N83729	003		Feb	DISC

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

>D>	AB	ABLE	75MG	N76114	001	Feb 06, 2002	May	DISC
>A>		@	75MG	N76114	001	Feb 06, 2002	May	DISC

CAPSULE; ORAL

INDOMETHACIN

>D>	AB	ABLE	25MG	N76666	001	Dec 17, 2003	May	DISC
>A>		@	25MG	N76666	001	Dec 17, 2003	May	DISC
>D>	AB		50MG	N76666	002	Dec 17, 2003	May	DISC
>A>		@	50MG	N76666	002	Dec 17, 2003	May	DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

	AN	BREATH LTD	0.02%	N76291	001	May 09, 2005	Apr	NEWA

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

	BP	+ WATSON LABS (UTAH)	EQ 50MG IRON/ML	N17441	001		Feb	CAHN

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

		+ LUITPOLD	EQ 100MG BASE/5ML(EQ 20MG BASE/ML)	N21135	001	Nov 06, 2000	Mar	CPOT
			EQ 50MG BASE/2.5ML(EQ 20MG BASE/ML)	N21135	002	Mar 20, 2005	Mar	NEWA
			EQ 75MG BASE/3.75ML(EQ 20MG BASE/ML)	N21135	003	Mar 29, 2005	Mar	NEWA

ISRADIPINE

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

		RELIANT PHARMS	5MG	N20336	001	Jun 01, 1994	Mar	CRLD

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX

		@ APOTHECON	EQ 500MG BASE	N62726	001	Mar 06, 1987	Feb	DISC

KETOCONAZOLE

SHAMPOO; TOPICAL

KETOCONAZOLE

	AB	QLT USA	2%	N76942	001	Apr 11, 2005	Mar	NEWA

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL

>D>	AB		WYETH PHARMS INC	100MG	N19816	003	Feb 08, 1995	May	DISC
>A>		@		100MG	N19816	003	Feb 08, 1995	May	DISC
>D>	AB			150MG	N19816	002	Feb 08, 1995	May	DISC
>A>		@		150MG	N19816	002	Feb 08, 1995	May	DISC

LACTULOSE

SOLUTION; ORAL

EVALOSE

	AA		TEVA PHARMS	10GM/15ML	N73497	001	May 28, 1993	Mar	CAHN

SOLUTION; ORAL, RECTAL

HEPTALAC

	AA		TEVA PHARMS	10GM/15ML	N73504	001	May 28, 1993	Mar	CAHN

LEPIRUDIN RECOMBINANT

INJECTABLE; INJECTION

REFLUDAN

		+	BERLEX	50MG/VIAL	N20807	001	Mar 06, 1998	Mar	CAIN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM PRESERVATIVE FREE

	AP	+	BEDFORD	EQ 10MG BASE/ML	N40347	001	Apr 25, 2000	Apr	CRLD
		@	HOSPIRA	EQ 10MG BASE/ML	N40147	001	Jun 25, 1997	Apr	DISC

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

ELIGARD

		+	QLT USA	22.5MG/VIAL	N21379	001	Jul 24, 2002	Jan	CAHN

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

		+	SEPRACOR	EQ 0.045MG BASE/INH	N21730	001	Mar 11, 2005	Mar	NEWA

LEVOFLOXACIN

TABLET; ORAL

LEVAQUIN

			ORTHO MCNEIL PHARM	250MG	N20634	001	Dec 20, 1996	Mar	CTEC
				500MG	N20634	002	Dec 20, 1996	Mar	CTEC
	AB	+		750MG	N20634	003	Sep 08, 2000	Jan	CFTG

LEVOFLOXACIN

	AB		TEVA	750MG	N76361	003	Jan 26, 2005	Jan	NEWA

LEVOTHYROXINE SODIUM**

**Refer to Preface Section 1.3 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVOTHYROXINE SODIUM

>A>	AB2		GENPHARM	0.025MG	N76752	001	Jun 16, 2005	May	NEWA
>A>	AB2			0.05MG	N76752	002	Jun 16, 2005	May	NEWA
>A>	AB2			0.075MG	N76752	003	Jun 16, 2005	May	NEWA
>A>	AB2			0.088MG	N76752	004	Jun 16, 2005	May	NEWA
>A>	AB2			0.1MG	N76752	005	Jun 16, 2005	May	NEWA
>A>	AB2			0.112MG	N76752	006	Jun 16, 2005	May	NEWA

TABLET; ORAL
LEVOTHYROXINE SODIUM

>A>	AB2	GENPHARM	0.125MG	N76752	007	Jun 16, 2005	May	NEWA
>A>	AB2		0.15MG	N76752	008	Jun 16, 2005	May	NEWA
>A>	AB2		0.175MG	N76752	009	Jun 16, 2005	May	NEWA
>A>	AB2		0.2MG	N76752	010	Jun 16, 2005	May	NEWA
>A>	AB2		0.3MG	N76752	011	Jun 16, 2005	May	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL PRESERVATIVE FREE

	AP	AM PHARM	2%	N17584	001		Apr	CAHN
	AP		4%	N17584	002		Apr	CAHN

JELLY; TOPICAL
LIDOCAINE HCL

	AT	TEVA PHARMS	2%	N81318	001	Apr 29, 1993	Mar	CAHN

LIOTHYRONINE SODIUM

TABLET; ORAL
CYTOMEL

>D>		JONES PHARMA	EQ 0.005MG BASE	N10379	001		May	CAHN
>D>			EQ 0.025MG BASE	N10379	002		May	CAHN
>D>	+		EQ 0.05MG BASE	N10379	003		May	CAHN
>A>		KING PHARMS	EQ 0.005MG BASE	N10379	001		May	CAHN
>A>			EQ 0.025MG BASE	N10379	002		May	CAHN
>A>	+		EQ 0.05MG BASE	N10379	003		May	CAHN

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE

>D>	AB	ABLE	150MG	N76823	001	Jun 29, 2004	May	DISC
>A>		@	150MG	N76823	001	Jun 29, 2004	May	DISC
>D>	AB		300MG	N76121	001	Sep 27, 2001	May	DISC
>A>		@	300MG	N76121	001	Sep 27, 2001	May	DISC
>D>	AB		300MG	N76823	002	Jun 29, 2004	May	DISC
>A>		@	300MG	N76823	002	Jun 29, 2004	May	DISC
>D>	AB		600MG	N76823	003	Jun 29, 2004	May	DISC
>A>		@	600MG	N76823	003	Jun 29, 2004	May	DISC
>D>	AB	+ ROXANE	600MG	N17812	003	Jan 28, 1987	May	CTEC
>A>		+	600MG	N17812	003	Jan 28, 1987	May	CTEC

TABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE

>D>	AB	ABLE	300MG	N76382	001	Apr 21, 2003	May	DISC
>A>		@	300MG	N76382	001	Apr 21, 2003	May	DISC

LORAZEPAM

SOLUTION; ORAL
LORAZEPAM

		ROXANE	0.5MG/5ML	N74648	001	Mar 18, 1997	Jan	CMFD

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON

	+	MYLAN BERTEK	EQ 85MG BASE/GM	N16763	001		Apr	CAHN

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION
TESLASCAN

	@ GE HEALTHCARE	37.9MG/ML	N20652	001	Nov 26, 1997	Jan	DISC	

MEBENDAZOLE

TABLET, CHEWABLE; ORAL
MEBENDAZOLE

AB	TEVA PHARMS	100MG	N73580	001	Jan 04, 1995	Mar	CAHN	

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HCL

	@ ABC HOLDING	12.5MG	N85253	001		Feb	DISC	
	@	25MG	N85252	001		Feb	DISC	

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGESTROL ACETATE

AB	TEVA PHARMS	40MG/ML	N75681	001	May 05, 2003	Mar	CAHN	

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL
NAMENDA

+	FOREST LABS	2MG/ML	N21627	001	Apr 18, 2005	Apr	NEWA	

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
SOLAGE

+	BARRIER	2%;0.01%	N20922	001	Dec 10, 1999	Feb	CAHN	

METAPROTERENOL SULFATE

SYRUP; ORAL
METAPROTERENOL SULFATE

	@ TEVA PHARMS	10MG/5ML	N73034	001	Aug 30, 1991	Mar	CAHN	

METAXALONE

TABLET; ORAL
SKELAXIN

>D>	JONES PHARMA INC	400MG	N13217	001		May	DISC	
>A>	@	400MG	N13217	001		May	DISC	

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HCL

AB	ANDRX PHARMS	750MG	N76869	001	Apr 12, 2005	Mar	NEWA	
AB	PUREPAC PHARM	750MG	N76878	001	Apr 13, 2005	Mar	NEWA	
AB	TEVA	750MG	N76864	001	Apr 12, 2005	Mar	NEWA	
AB	ZYDUS PHARMS USA	500MG	N77060	001	Apr 20, 2005	Mar	NEWA	
AB		750MG	N77078	001	Apr 21, 2005	Apr	NEWA	

TABLET; ORAL
METFORMIN HCL

AB	ZYDUS PHARMS USA	500MG	N77064	001	Apr 18, 2005	Mar	NEWA	
AB		850MG	N77064	002	Apr 18, 2005	Mar	NEWA	
AB		1GM	N77064	003	Apr 18, 2005	Mar	NEWA	

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

			DESOXYN							
>D>	AB	+	OVATION PHARMS	5MG	N05378	002		May	CTEC
>A>		+		5MG	N05378	002		May	CTEC
			METHAMPHETAMINE HCL							
>D>	AB		ABLE	5MG	N40529	001	Feb 25, 2004	May	DISC
>A>			@	5MG	N40529	001	Feb 25, 2004	May	DISC

METHAZOLAMIDE

TABLET; ORAL

		METHAZOLAMIDE							
	AB		TEVA PHARMS	25MG	N40001	001	Jun 30, 1993	Mar	CAHN
	AB			50MG	N40001	002	Jun 30, 1993	Mar	CAHN

METHIMAZOLE

TABLET; ORAL

		METHIMAZOLE							
	AB		CEDAR PHARMS	5MG	N40547	001	Feb 18, 2005	Jan	NEWA
	AB			10MG	N40547	002	Feb 18, 2005	Jan	NEWA
	AB			20MG	N40547	004	Feb 18, 2005	Jan	NEWA
			@ GENPHARM	20MG	N40350	003	Jun 07, 2001	Apr	DISC
	AB	+		20MG	N40350	003	Jun 07, 2001	Jan	CFTG

METHOCARBAMOL

TABLET; ORAL

		METHOCARBAMOL							
>D>	AA		ABLE	500MG	N40413	001	Mar 17, 2003	May	DISC
>A>			@	500MG	N40413	001	Mar 17, 2003	May	DISC
>D>	AA			750MG	N40413	002	Mar 17, 2003	May	DISC
>A>			@	750MG	N40413	002	Mar 17, 2003	May	DISC

METHOTREXATE SODIUM

INJECTABLE; INJECTION

		METHOTREXATE							
		@	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40263	001	Feb 26, 1999	Apr	DISC
	AP	+	MAYNE PHARMA USA	EQ 50MG BASE/2ML (25 MG/ML)	N11719	010	Dec 15, 2004	Apr	NEWA
		METHOTREXATE LPF							
		@	MAYNE PHARMA USA	EQ 25MG BASE/ML	N11719	007	Mar 31, 1982	Apr	DISC
		METHOTREXATE PRESERVATIVE FREE							
		@	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40265	001	Feb 26, 1999	Apr	DISC
		@		EQ 1GM BASE/VIAL	N40266	001	Feb 26, 1999	Apr	DISC
		+	MAYNE PHARMA USA	EQ 20MG BASE/2ML (10 MG/ML)	N11719	014	Apr 13, 2005	Apr	NEWA
	AP	+		EQ 500MG BASE/20ML (25 MG/ML)	N11719	013	Apr 13, 2005	Apr	NEWA
	AP	+		ED 1GM BASE/40ML (25 MG/ML)	N11719	012	Apr 13, 2005	Apr	NEWA
	AP	+		EQ 2.5GM BASE/100ML (25 MG/ML)	N11719	011	Apr 13, 2005	Apr	NEWA
		METHOTREXATE SODIUM							
	AP		BEDFORD	EQ 50 MG BASE/2ML (25 ML/ML)	N89340	001	Sep 16, 1986	Apr	CPOT
	AP			EQ 100MG BASE/4ML (25 MG/ML)	N89341	001	Sep 16, 1986	Apr	CPOT
	AP			EQ 200MG BASE/8ML (25 MG/ML)	N89342	001	Sep 16, 1986	Apr	CPOT
	AP			EQ 250MG BASE/10ML (25 MG/ML)	N89343	001	Sep 16, 1986	Apr	CPOT
		@	MAYNE PHARMA USA	EQ 20MG BASE/VIAL	N11719	001		Mar	DISC
		@		EQ 25MG BASE/ML	N11719	005		Apr	DISC
		@	NORBROOK	EQ 25MG BASE/ML	N88648	001	May 09, 1986	Apr	DISC
		@	PHARMACHEMIE USA	EQ 25MG BASE/ML	N89158	001	Jul 08, 1988	Apr	DISC

		INJECTABLE; INJECTION							
		MEXATE-AQ							
		@ BRISTOL MYERS	EQ 25MG BASE/ML	N88760	001	Feb 14, 1985	Apr	DISC	
		METHYL AMINOLEVULINATE HYDROCHLORIDE							
		CREAM; TOPICAL							
>D>		METHYL AMINOLEVULINATE							
>D>		+ PHOTOCURE ASA	16.8%	N21415	001	Jul 27, 2004	May	CTNA	
>A>		METVIXIA							
>A>		+ PHOTOCURE ASA	16.8%	N21415	001	Jul 27, 2004	May	CTNA	
		METHYLDOPA							
		TABLET; ORAL							
		ALDOMET							
		@ MERCK	500MG	N13400	002		Jan	DISC	
		METHYLDOPA							
	AB	+ MYLAN	500MG	N70076	001	Apr 18, 1985	Jan	CRLD	
		METHYLDOPATE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		ALDOMET							
		@ MERCK	50MG/ML	N13401	001		Jan	DISC	
		METHYLDOPATE HCL							
	AP	+ LUITPOLD	50MG/ML	N71279	001	Oct 02, 1987	Jan	CRLD	
		METHYLERGONOVINE MALEATE							
		TABLET; ORAL							
		METHERGINE							
		+ NOVARTIS	0.2MG	N06035	003		Jan	CRLD	
		METHYLPHENIDATE HYDROCHLORIDE							
		TABLET, EXTENDED RELEASE; ORAL							
		METHYLPHENIDATE HCL							
>D>	AB	ABLE	20MG	N76032	001	May 09, 2001	May	DISC	
>A>		@	20MG	N76032	001	May 09, 2001	May	DISC	
		TABLET; ORAL							
		METHYLPHENIDATE HCL							
>D>	AB	ABLE	5MG	N40404	001	Mar 29, 2001	May	DISC	
>A>		@	5MG	N40404	001	Mar 29, 2001	May	DISC	
>D>	AB		10MG	N40404	002	Mar 29, 2001	May	DISC	
>A>		@	10MG	N40404	002	Mar 29, 2001	May	DISC	
>D>	AB		20MG	N40404	003	Mar 29, 2001	May	DISC	
>A>		@	20MG	N40404	003	Mar 29, 2001	May	DISC	
		METHYLPREDNISOLONE ACETATE							
		INJECTABLE; INJECTION							
		DEPO-MEDROL							
	AB	+ PHARMACIA AND UPJOHN	40MG/ML	N11757	001		Feb	CFTG	
	AB	+	80MG/ML	N11757	004		Feb	CFTG	
		METHYLPREDNISOLONE ACETATE							
	AB	SICOR PHARMS	40MG/ML	N40557	001	Feb 23, 2005	Feb	NEWA	
	AB		80MG/ML	N40557	002	Feb 23, 2005	Feb	NEWA	

METOLAZONE

TABLET; ORAL
ZAROXOLYN

AB		UCB	2.5MG	N17386	001		Mar	CAHN
AB	+		5MG	N17386	002		Mar	CAHN
AB	+		10MG	N17386	003		Mar	CAHN

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

AB		TEVA PHARMS	50MG	N74333	001	Jan 27, 1994	Mar	CAHN
AB			100MG	N74333	002	Jan 27, 1994	Mar	CAHN

METRONIDAZOLE

CAPSULE; ORAL
METRONIDAZOLE

>D>	AB	ABLE	375MG	N76505	001	Nov 13, 2003	May	DISC
>A>		@	375MG	N76505	001	Nov 13, 2003	May	DISC

GEL; VAGINAL
METROGEL-VAGINAL

>D>		+ 3M	0.75%	N20208	001	Aug 17, 1992	May	CTEC
>A>	BX	+	0.75%	N20208	001	Aug 17, 1992	May	CTEC
>A>		METRONIDAZOLE						
>A>	BX	TEVA PHARMS	0.75%	N21806	001	May 20, 2005	May	NEWA

TABLET, EXTENDED RELEASE; ORAL
FLAGYL ER

>D>	AB	+ GD SEARLE LLC	750MG	N20868	001	Nov 26, 1997	May	CTEC
>A>		+	750MG	N20868	001	Nov 26, 1997	May	CTEC

METRONIDAZOLE

>D>	AB	ABLE	750MG	N76462	001	Jun 25, 2003	May	DISC
>A>		@	750MG	N76462	001	Jun 25, 2003	May	DISC

TABLET; ORAL
METRONIDAZOLE

>D>	AB	ABLE	250MG	N76519	001	Jun 27, 2003	May	DISC
>A>		@	250MG	N76519	001	Jun 27, 2003	May	DISC
>D>	AB		500MG	N76519	002	Jun 27, 2003	May	DISC
>A>		@	500MG	N76519	002	Jun 27, 2003	May	DISC

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)
MYCAMINE

	+	ASTELLAS	50MG/VIAL	N21506	002	Mar 16, 2005	Mar	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

AP		HOSPIRA	EQ 1MG BASE/ML	N75293	001	Jun 20, 2000	Mar	CMFD
AP			EQ 5MG BASE/ML	N75293	002	Jun 20, 2000	Mar	CMFD
AP		INTL MEDICATED	EQ 1MG BASE/ML	N76144	001	Jan 26, 2005	Jan	NEWA
AP			EQ 5MG BASE/ML	N76144	002	Jan 26, 2005	Jan	NEWA

SYRUP; ORAL
MIDAZOLAM HCL

AA		PADDOCK	EQ 2MG BASE/ML	N76379	001	May 02, 2005	Apr	NEWA

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCIN

>D>	AB	WYETH PHARMS INC	EQ 75MG BASE	N50649	003	Feb 12, 2001	May	DISC
>A>		@	EQ 75MG BASE	N50649	003	Feb 12, 2001	May	DISC

>D> INJECTABLE; INJECTION
>D> MINOCIN

>D>	+	WYETH PHARMS INC	EQ 100MG BASE/VIAL	N50444	001		May	DISC
>A>		@	EQ 100MG BASE/VIAL	N50444	001		May	DISC

MOMETASONE FUROATE

CREAM; TOPICAL
ELOCON

AB	+	SCHERING	0.1%	N19625	001	May 06, 1987	Jan	CFTG

MOMETASONE FUROATE

AB		ALTANA	0.1%	N76171	001	Apr 08, 2005	Mar	NEWA
AB		TARO	0.1%	N76679	001	Dec 21, 2004	Jan	NEWA

LOTION; TOPICAL
ELOCON

AB	+	SCHERING	0.1%	N19796	001	Mar 30, 1989	Mar	CFTG

MOMETASONE FUROATE

AB		AGIS INDS	0.1%	N77180	001	Apr 06, 2005	Mar	NEWA

OINTMENT; TOPICAL
MOMETASONE FUROATE

AB		ALTANA	0.1%	N77061	001	Mar 28, 2005	Mar	NEWA

POWDER; INHALATION
ASMANEX TWISTHALER

	+	SCHERING	0.22MG/INH	N21067	001	Mar 30, 2005	Mar	NEWA

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL
NASONEX

	+	SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY	N20762	001	Oct 01, 1997	Apr	CAHN
	+	SHIRE	EQ 0.05MG BASE/SPRAY	N20762	001	Oct 01, 1997	Mar	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
AVINZA

BX		LIGAND	30MG	N21260	001	Mar 20, 2002	Mar	CRLD
BX			60MG	N21260	002	Mar 20, 2002	Mar	CRLD
			90MG	N21260	003	Mar 20, 2002	Mar	CRLD

KADIAN

		ALPHARMA US PHARMS	20MG	N20616	001	Jul 03, 1996	Mar	CRLD
BX			30MG	N20616	004	Mar 09, 2001	Mar	CRLD
			50MG	N20616	002	Jul 03, 1996	Mar	CRLD
BX			60MG	N20616	005	Mar 09, 2001	Mar	CRLD

NADOLOL

TABLET; ORAL
NADOLOL

AB		TEVA PHARMS	80MG	N74368	001	Aug 31, 1994	Mar	CAHN
AB			120MG	N74368	002	Aug 31, 1994	Mar	CAHN
AB			160MG	N74368	003	Aug 31, 1994	Mar	CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

AP	HOSPIRA	0.4MG/ML	N70172	001	Sep 24, 1986	Mar	CMFD

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

>A> AB	ALPHAPHARM	375MG	N75390	001	Apr 19, 2001	May	CDFR
>A> AB		500MG	N75390	002	Apr 19, 2001	May	CDFR

>D> TABLET, EXTENDED RELEASE; ORAL

>D> NAPROXEN

>D> AB +	ALPHAPHARM	375MG	N75390	001	Apr 19, 2001	May	CDFR
>D> AB +		500MG	N75390	002	Apr 19, 2001	May	CDFR

TABLET; ORAL

NAPROXEN

AB	PERRIGO R AND D	250MG	N77339	001	Apr 27, 2005	Apr	NEWA
AB		375MG	N77339	002	Apr 27, 2005	Apr	NEWA
AB		500MG	N77339	003	Apr 27, 2005	Apr	NEWA
AB	TEVA PHARMS	250MG	N74207	001	Dec 21, 1993	Mar	CAHN
AB		375MG	N74207	002	Dec 21, 1993	Mar	CAHN
AB		500MG	N74207	003	Dec 21, 1993	Mar	CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

>D> AB	ABLE	EQ 250MG BASE	N76544	001	Aug 22, 2003	May	DISC
>A> @		EQ 250MG BASE	N76544	001	Aug 22, 2003	May	DISC
>D> AB		EQ 500MG BASE	N76544	002	Aug 22, 2003	May	DISC
>A> @		EQ 500MG BASE	N76544	002	Aug 22, 2003	May	DISC
AB	TEVA PHARMS	EQ 250MG BASE	N74289	001	Jan 27, 1994	Mar	CAHN
AB		EQ 500MG BASE	N74289	002	Jan 27, 1994	Mar	CAHN

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HCL

>D> AB	TEVA	250MG	N76037	005	Sep 16, 2003	May	CRLD
>A> AB +		250MG	N76037	005	Sep 16, 2003	May	CRLD

>D> SERZONE

>D> AB	BRISTOL MYERS SQUIBB	50MG	N20152	001	Dec 22, 1994	May	DISC
>A> @		50MG	N20152	001	Dec 22, 1994	May	DISC
>D> AB		100MG	N20152	002	Dec 22, 1994	May	DISC
>A> @		100MG	N20152	002	Dec 22, 1994	May	DISC
>D> AB		150MG	N20152	003	Dec 22, 1994	May	DISC
>A> @		150MG	N20152	003	Dec 22, 1994	May	DISC
>D> AB		200MG	N20152	004	Dec 22, 1994	May	DISC
>A> @		200MG	N20152	004	Dec 22, 1994	May	DISC
>D> AB +		250MG	N20152	005	Dec 22, 1994	May	DISC
>A> @		250MG	N20152	005	Dec 22, 1994	May	DISC

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

+	SCIOS	1.5MG/VIAL	N20920	001	Aug 10, 2001	Apr	CAIN

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB		BARR	500MG	N76378	001	Apr 26, 2005	Apr	NEWA
AB			750MG	N76378	002	Apr 26, 2005	Apr	NEWA
AB			1GM	N76250	001	Apr 14, 2005	Mar	NEWA

NIASPAN

AB	+	KOS	500MG	N20381	002	Jul 28, 1997	Apr	CFTG
AB	+		750MG	N20381	003	Jul 28, 1997	Apr	CFTG
AB	+		1GM	N20381	004	Jul 28, 1997	Mar	CFTG

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARDENE

	+	ESP PHARMA	2.5MG/ML	N19734	001	Jan 30, 1992	Mar	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		EON	75MG;25MG	N77066	001	Apr 05, 2005	Mar	NEWA
AB		RANBAXY	75MG;25MG	N76951	001	Mar 30, 2005	Mar	NEWA

NYSTATIN

POWDER; TOPICAL

NYSTATIN

AT		UPSHER SMITH	100,000 UNITS/GM	N65183	001	May 03, 2005	Apr	NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP		BEDFORD	EQ 0.2MG BASE/ML	N76330	001	Apr 08, 2005	Mar	NEWA
AP			EQ 1MG BASE/ML	N76330	002	Apr 08, 2005	Mar	NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP		BEDFORD	EQ 0.05MG BASE/ML	N76313	001	Mar 28, 2005	Mar	NEWA
AP			EQ 0.1MG BASE/ML	N76313	003	Mar 28, 2005	Mar	NEWA
AP			EQ 0.5MG BASE/ML	N76313	002	Mar 28, 2005	Mar	NEWA

SANDOSTATIN

AP	+	NOVARTIS	EQ 0.05MG BASE/ML	N19667	001	Oct 21, 1988	Mar	CFTG
AP	+		EQ 0.1MG BASE/ML	N19667	002	Oct 21, 1988	Mar	CFTG
AP	+		EQ 0.2MG BASE/ML	N19667	004	Jun 12, 1991	Mar	CFTG
AP	+		EQ 0.5MG BASE/ML	N19667	003	Oct 21, 1988	Mar	CFTG
AP	+		EQ 1MG BASE/ML	N19667	005	Jun 12, 1991	Mar	CFTG

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

	+	UCB	250MG	N19715	001	Jul 31, 1990	Mar	CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PRILOSEC

	+	ASTRAZENECA	40MG	N19810	002	Jan 15, 1998	Apr	CRLD
			40MG	N19810	002	Jan 15, 1998	Mar	CTEC

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

	+	SANOFI	50MG/VIAL	N21492	001	Aug 09, 2002	Mar	CRLD
	+	SANOFI SYNTHELABO	50MG/10ML (5MG/ML)	N21759	001	Jan 31, 2005	Jan	NEWA
	+		100MG/20ML (5MG/ML)	N21759	002	Jan 31, 2005	Jan	NEWA

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AB	+	IVAX PHARMS	30MG	N70945	001	Aug 03, 1987	Apr	CRLD

SERAX

	@	ALPHARMA US PHARMS	10MG	N15539	002		Apr	DISC
	@		15MG	N15539	004		Apr	DISC
	@		30MG	N15539	006		Apr	DISC

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

NUMORPHAN

>D>	+	ENDO PHARMS	1.5MG/ML	N11707	001		May	DISC
>A>	@		1.5MG/ML	N11707	001		May	DISC

>D> SUPPOSITORY; RECTAL

>D> NUMORPHAN

>D>	+	ENDO PHARMS	5MG	N11738	004		May	DISC
>A>	@		5MG	N11738	004		May	DISC

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

	+	AM BIOSCIENCE	100MG/VIAL	N21660	001	Jan 07, 2005	Jan	NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

>D>	AP	BEDFORD	30MG /10ML(3MG/ML)	N21113	001	Mar 04, 2002	May	CRLD
>A>	AP	+	30MG /10ML(3MG/ML)	N21113	001	Mar 04, 2002	May	CRLD
>D>	AP	MAYNE PHARMA USA	EQ 30MG /10ML(3MG/ML)	N75841	001	Jun 27, 2002	May	CRLD
>A>	AP	+	EQ 30MG /10ML(3MG/ML)	N75841	001	Jun 27, 2002	May	CRLD
>D>	AP		EQ 60MG /10ML(6MG/ML)	N75841	002	Jun 27, 2002	May	CRLD
>A>	AP	+	EQ 60MG /10ML(6MG/ML)	N75841	002	Jun 27, 2002	May	CRLD
>D>	AP		EQ 90MG /10ML(9MG/ML)	N75841	003	Jun 27, 2002	May	CRLD
>A>	AP	+	EQ 90MG /10ML(9MG/ML)	N75841	003	Jun 27, 2002	May	CRLD

PARICALCITOL

>A> CAPSULE; ORAL

>A> ZEMPLAR

>A>		ABBOTT	1UGM	N21606	001	May 26, 2005	May	NEWA
>A>			2UGM	N21606	002	May 26, 2005	May	NEWA
>A>	+		4UGM	N21606	003	May 26, 2005	May	NEWA

PEMOLINE

TABLET, CHEWABLE; ORAL

PEMOLINE

AB		TEVA PHARMS	37.5MG	N75555	001	Feb 18, 2000	Mar	CAHN

		TABLET; ORAL							
		PEMOLINE							
	AB	TEVA PHARMS	18.75MG	N75030	003	Feb 22, 2000	Mar	CAHN	
	AB		37.5MG	N75030	001	Jan 29, 1999	Mar	CAHN	
	AB		75MG	N75030	002	Jan 29, 1999	Mar	CAHN	
		PENTOBARBITAL SODIUM							
		CAPSULE; ORAL							
		SODIUM PENTOBARBITAL							
		@ VALEANT PHARM INTL	100MG	N83264	001		Jan	DISC	
		PHENDIMETRAZINE TARTRATE							
		TABLET; ORAL							
		BONTRIL PDM							
	AA +	VALEANT	35MG	N85272	001		Feb	CRLD	
		CAM-METRAZINE							
		@ ABC HOLDING	35MG	N83922	001		Feb	DISC	
		@	35MG	N85318	001		Feb	DISC	
		@	35MG	N85320	001		Feb	DISC	
		@	35MG	N85321	001		Feb	DISC	
		@	35MG	N85511	001		Feb	DISC	
		@ CAMALL	35MG	N85756	001		Feb	DISC	
		PHENDIMETRAZINE TARTRATE							
		@ ABC HOLDING	35MG	N85761	001		Feb	DISC	
		@	35MG	N85941	001	Jun 27, 1983	Feb	DISC	
		@ EON	35MG	N85830	001		Feb	DISC	
		X-TROZINE							
		@ SHIRE RICHWOOD	35MG	N86553	001		Feb	DISC	
		@	35MG	N86554	001		Feb	DISC	
		PHENTERMINE HYDROCHLORIDE							
		CAPSULE; ORAL							
		ONA-MAST							
		@ MAST MM	30MG	N86511	001		Feb	DISC	
		@	30MG	N86516	001		Feb	DISC	
		PHENTERMINE HCL							
		@ ABC HOLDING	18.75MG	N88576	001	May 23, 1984	Feb	DISC	
		@	30MG	N85417	001		Feb	DISC	
		@	30MG	N86732	002		Feb	DISC	
		@	30MG	N87215	001		Feb	DISC	
		@	37.5MG	N87915	001	Dec 22, 1983	Feb	DISC	
		@	37.5MG	N87918	001	Dec 22, 1983	Feb	DISC	
		@	37.5MG	N87930	001	Oct 14, 1983	Feb	DISC	
		@	37.5MG	N88610	001	Jun 04, 1984	Feb	DISC	
		@	37.5MG	N88611	001	Jun 04, 1984	Feb	DISC	
		@	37.5MG	N88625	001	Aug 23, 1984	Feb	DISC	
>D>	AA	ABLE	15MG	N40497	001	Mar 13, 2003	May	DISC	
>A>		@	15MG	N40497	001	Mar 13, 2003	May	DISC	
>D>	AA		30MG	N40403	001	Aug 30, 2001	May	DISC	
>A>		@	30MG	N40403	001	Aug 30, 2001	May	DISC	
>D>	AA		30MG	N40427	001	Aug 30, 2001	May	DISC	
>A>		@	30MG	N40427	001	Aug 30, 2001	May	DISC	
		@ CAMALL	15MG	N86735	001		Feb	DISC	
		@	30MG	N87226	001		Feb	DISC	
		TABLET; ORAL							
		ONA MAST							
		@ MAST MM	8MG	N86260	001		Feb	DISC	

TABLET; ORAL
PHENTERMINE HCL

	@ ABC HOLDING	8MG	N83923	001		Feb	DISC	
	@	8MG	N85319	001		Feb	DISC	
	@	37.5MG	N87805	001	Dec 06, 1982	Feb	DISC	
	@	37.5MG	N88596	001	Apr 04, 1984	Feb	DISC	
>D> AA	ABLE	37.5MG	N40402	001	Aug 30, 2001	May	DISC	
>A>	@	37.5MG	N40402	001	Aug 30, 2001	May	DISC	
AA	LANNETT	37.5MG	N40555	001	Apr 15, 2005	Mar	NEWA	

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
IONAMIN

	UCB	EQ 15MG BASE	N11613	004		Mar	CAHN	
+		EQ 30MG BASE	N11613	002		Mar	CAHN	

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN

AP +	ELKINS SINN	50MG/ML	N84307	001		Mar	CTEC	

PHENYTOIN SODIUM

AP	HOSPIRA	50MG/ML	N89521	001	Mar 17, 1987	Mar	CMFD	
AP		50MG/ML	N89744	001	Dec 18, 1987	Mar	CMFD	

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	TEVA PHARMS	10MG	N74103	001	Aug 28, 1992	Mar	CAHN	
AB		20MG	N74103	002	Aug 28, 1992	Mar	CAHN	

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	HOSPIRA	14.9MG/ML	N20161	005	Nov 30, 1992	Mar	CMFD	
AP		745MG/100ML	N20161	001	Nov 30, 1992	Mar	CMFD	

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	HOSPIRA	1.49GM/100ML	N20161	002	Nov 30, 1992	Mar	CMFD	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL
UROCIT-K

	MISSION PHARMA	5MEQ	N19071	001	Aug 30, 1985	Jan	CTNA	
+		10MEQ	N19071	002	Aug 31, 1992	Jan	CTNA	

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS
SYMLIN

+	AMYLIN	EQ 3MG BASE/5ML (EQ 0.6MG BASE/ML)	N21332	001	Mar 16, 2005	Mar	NEWA	

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

AA	IVAX PHARMS	15MG/5ML	N40287	001	May 28, 1999	Jan	CAHN	
AA	TEVA PHARMS	15MG/5ML	N40322	001	Jan 19, 2000	Mar	CAHN	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

AA	+	UCB	EQ 5MG BASE/5ML	N19157	001	May 28, 1986	Mar	CAHN

PREDNISOLONE SODIUM PHOSPHATE

>A> AA		KV PHARM	EQ 5MG BASE/5ML	N76982	001	May 24, 2005	May	NEWA
>A> AA			EQ 15MG BASE/5ML	N76988	001	May 24, 2005	May	NEWA
AA		PHARM ASSOC	EQ 15MG BASE/5ML	N76913	001	Apr 25, 2005	Apr	NEWA

PREDNISONE

TABLET; ORAL

PREDNISONE

>A> AB		TRIGEN	1MG	N40611	001	Jun 06, 2005	May	NEWA

PRIMIDONE

TABLET; ORAL

MYSOLINE

AB	+	VALEANT	50MG	N09170	003		Apr	CAHN
AB			250MG	N09170	002		Apr	CAHN

PRIMIDONE

AB		VINTAGE PHARMS	50MG	N40586	001	Feb 24, 2005	Feb	NEWA
AB			250MG	N40586	002	Feb 24, 2005	Feb	NEWA

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

>D> AB		GLAXOSMITHKLINE	2.5MG	N11127	003		May	CTEC
>A>			2.5MG	N11127	003		May	CTEC
>D> AB			5MG	N11127	001		May	CTEC
>A>			5MG	N11127	001		May	CTEC

PROCHLORPERAZINE

>D> AB		ABLE	2.5MG	N40407	001	Jul 11, 2001	May	DISC
>A>		@	2.5MG	N40407	001	Jul 11, 2001	May	DISC
>D> AB			5MG	N40407	002	Jul 11, 2001	May	DISC
>A>		@	5MG	N40407	002	Jul 11, 2001	May	DISC
>D> AB			25MG	N40407	003	Jul 11, 2001	May	DISC
>A>		@	25MG	N40407	003	Jul 11, 2001	May	DISC

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

AB		TEVA PHARMS	EQ 5MG BASE	N40120	001	Jul 11, 1996	Mar	CAHN
AB			EQ 10MG BASE	N40120	002	Jul 11, 1996	Mar	CAHN

PROGESTERONE

INJECTABLE; INJECTION

PROGESTERONE

AO	+	WATSON LABS (UTAH)	50MG/ML	N17362	002		Feb	CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PHENERGAN

>D> AB	+	WYETH PHARMS INC	50MG	N11689	001		May	CTEC
>A>	+		50MG	N11689	001		May	CTEC

SUPPOSITORY; RECTAL
PROMETHAZINE HCL

>D>	AB	ABLE	12.5MG	N40504	001	Apr 11, 2003	May	DISC
>A>		@	12.5MG	N40504	001	Apr 11, 2003	May	DISC
>D>	AB		25MG	N40504	002	Apr 11, 2003	May	DISC
>A>		@	25MG	N40504	002	Apr 11, 2003	May	DISC
>D>	AB		50MG	N40449	001	Feb 27, 2003	May	DISC
>A>		@	50MG	N40449	001	Feb 27, 2003	May	DISC

TABLET; ORAL
PHENERGAN

>D>	AB	WYETH PHARMS INC	25MG	N07935	003		May	CTEC
>A>			25MG	N07935	003		May	CTEC
>D>	AB +		50MG	N07935	004		May	DISC
>A>		@	50MG	N07935	004		May	DISC

PROMETHAZINE HCL

>D>		ABLE	12.5MG	N40558	001	Jul 01, 2004	May	DISC
>A>		@	12.5MG	N40558	001	Jul 01, 2004	May	DISC
			12.5MG	N40558	001	Jul 01, 2004	Jan	CTEC
>D>	AB		25MG	N40558	002	Jul 01, 2004	May	DISC
>A>		@	25MG	N40558	002	Jul 01, 2004	May	DISC
>D>	AB		50MG	N40558	003	Jul 01, 2004	May	DISC
>A>		@	50MG	N40558	003	Jul 01, 2004	May	DISC

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL

	AB	BEDFORD	10MG/ML	N74848	001	Apr 19, 2005	Mar	NEWA

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
INDERAL

	AB	WYETH PHARMS INC	10MG	N16418	001		Apr	CRLD

QUAZEPAM

TABLET; ORAL
DORAL

>D>		MEDPOINTE PHARM HLC	7.5MG	N18708	003	Feb 26, 1987	May	DISC
>A>		@	7.5MG	N18708	003	Feb 26, 1987	May	DISC

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HCL

	AB	EON	EQ 5MG BASE	N76803	001	Mar 02, 2005	Feb	NEWA
	AB		EQ 10MG BASE	N76803	002	Mar 02, 2005	Feb	NEWA
	AB		EQ 20MG BASE	N76803	003	Mar 02, 2005	Feb	NEWA
	AB		EQ 40MG BASE	N76803	004	Mar 02, 2005	Feb	NEWA
	AB	PAR PHARM	EQ 5MG BASE	N76036	001	Jan 28, 2005	Jan	NEWA
	AB		EQ 10MG BASE	N76036	002	Jan 28, 2005	Jan	NEWA
	AB		EQ 20MG BASE	N76036	003	Jan 28, 2005	Jan	NEWA
	AB		EQ 40MG BASE	N76036	004	Jan 28, 2005	Jan	NEWA

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE SULFATE

	+	TEVA PHARMS	300MG	N40045	001	Jun 30, 1994	Mar	CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
RANITIDINE HCL

AP	BEN VENUE	EQ 25MG BASE/ML	N74777	001	Mar 02, 2005	Feb	NEWA

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL
NAQUIVAL

	@ SCHERING	0.1MG;4MG	N12265	003		Feb	DISC

SIROLIMUS

TABLET; ORAL
RAPAMUNE

>D>	WYETH PHARMS INC	2MG	N21110	002	Aug 22, 2002	May	CRLD
>A>	+	2MG	N21110	002	Aug 22, 2002	May	CRLD
>D>	+	5MG	N21110	003	Feb 23, 2004	May	DISC
>A>	@	5MG	N21110	003	Feb 23, 2004	May	DISC

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)
AMMONUL

	+ UCYCLYD	10%;10% (5GM/50ML;5GM/50ML)	N20645	001	Feb 17, 2005	Feb	NEWA

SODIUM CHLORIDE

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AT	HOSPIRA	450MG/100ML	N18380	001		Mar	CMFD

SOMATREM

INJECTABLE; INJECTION
PROTROPIN

	@ GENENTECH	5MG/VIAL	N19107	001	Oct 17, 1985	Mar	DISC
	@	10MG/VIAL	N19107	002	Oct 24, 1989	Mar	DISC

SOMATROPIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS
SEROSTIM LQ

	SERONO	6MG/0.05VIAL	N20604	005	Feb 11, 2005	Feb	NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
ANECTINE

>D>	+ SABEX 2002	500MG/VIAL	N08453	001		May	DISC
>A>	@	500MG/VIAL	N08453	001		May	DISC
>D>	+	1GM/VIAL	N08453	004		May	DISC
>A>	@	1GM/VIAL	N08453	004		May	DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	INTERPHARM	400MG;80MG	N76899	001	Jan 27, 2005	Jan	NEWA
AB		800MG;160MG	N76899	002	Jan 27, 2005	Jan	NEWA

TACROLIMUS

CAPSULE; ORAL
PROGRAF

>D>		+	ASTELLAS	EQ 1MG BASE	N50708	001	Apr 08, 1994	May	CRLD
>A>				EQ 1MG BASE	N50708	001	Apr 08, 1994	May	CRLD
		+	FUJISAWA HLTHCARE	EQ 1MG BASE	N50708	001	Apr 08, 1994	Jan	CRLD

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

		@	PHARMACHEMIE	EQ 10MG BASE	N74539	001	Mar 31, 2003	Feb	DISC

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
OSTEOLITE

>D>									
>D>	AP		CIS	N/A	N17972	001		May	DISC
>A>			@	N/A	N17972	001		May	DISC

TELITHROMYCIN

TABLET; ORAL
KETEK

			AVENTIS PHARMS	300MG	N21144	002	Feb 09, 2005	Feb	NEWA

TERBUTALINE SULFATE

TABLET; ORAL
TERBUTALINE SULFATE

	AB		LANNETT	2.5MG	N77152	001	Mar 25, 2005	Mar	NEWA
	AB			5MG	N77152	002	Mar 25, 2005	Mar	NEWA

TERCONAZOLE

CREAM; VAGINAL
TERCONAZOLE

	AB		ALTANA	0.4%	N76712	001	Feb 18, 2005	Jan	NEWA

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
TESTOSTERONE CYPIONATE

	AO		PADDOCK	200MG/ML	N40530	001	Jan 31, 2005	Jan	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
SUMYCIN

			@ APOTHECON	250MG	N60429	001		Mar	DISC
			@	500MG	N60429	003		Mar	DISC

TETRACYCLINE HCL

	AB	+	IVAX PHARMS	500MG	N60704	002		Mar	CRLD
			@ MAST MM	250MG	N62085	001		Feb	DISC

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOPHYLLINE

			INWOOD LABS	125MG	N40052	002	Feb 14, 1994	Apr	CTEC

TABLET, EXTENDED RELEASE; ORAL
THEOPHYLLINE

>D>	AB		ABLE	300MG	N40548	001	Apr 30, 2004	May	DISC

TABLET, EXTENDED RELEASE; ORAL
THEOPHYLLINE

>A>			@ ABLE	300MG	N40548	001	Apr 30, 2004	May	DISC
>D>	AB			400MG	N40543	001	Apr 27, 2004	May	DISC
>A>			@	400MG	N40543	001	Apr 27, 2004	May	DISC
>D>	AB			450MG	N40546	001	Apr 30, 2004	May	DISC
>A>			@	450MG	N40546	001	Apr 30, 2004	May	DISC
>D>	AB			600MG	N40539	001	Apr 27, 2004	May	DISC
>A>			@	600MG	N40539	001	Apr 27, 2004	May	DISC

UNIPHYL

>D>	AB	+	PURDUE FREDERICK	400MG	N87571	001	Sep 01, 1982	May	CTEC
>A>		+		400MG	N87571	001	Sep 01, 1982	May	CTEC
>D>	AB	+		600MG	N40086	001	Apr 15, 1996	May	CTEC
>A>		+		600MG	N40086	001	Apr 15, 1996	May	CTEC

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

	AA	+	TEVA PHARMS	30MG/ML	N89602	001	Nov 09, 1987	Mar	CAHN
	AA	+		100MG/ML	N89603	001	Nov 09, 1987	Mar	CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

	AA		TEVA PHARMS	EQ 5MG BASE/ML	N71554	001	Oct 16, 1987	Mar	CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
DETROL LA

			PHARMACIA AND UPJOHN	2MG	N21228	001	Dec 22, 2000	Apr	CRLD

TOREMIFENE CITRATE

TABLET; ORAL
FARESTON

		+	GTX INC	EQ 60MG BASE	N20497	001	May 29, 1997	Jan	CAHN

TORSEMIDE

TABLET; ORAL
TORSEMIDE

>A>	AB		APOTEX	5MG	N76894	001	May 31, 2005	May	NEWA
>A>	AB			10MG	N76894	002	May 31, 2005	May	NEWA
>A>	AB			20MG	N76894	003	May 31, 2005	May	NEWA
>A>	AB			100MG	N76894	004	May 31, 2005	May	NEWA
	AB		ROXANE	5MG	N76943	001	Mar 01, 2005	Feb	NEWA
	AB			10MG	N76943	002	Mar 01, 2005	Feb	NEWA
	AB			20MG	N76943	003	Mar 01, 2005	Feb	NEWA

TRAMADOL HYDROCHLORIDE

>A> TABLET, ORALLY DISINTEGRATING; ORAL
>A> TRAMADOL HYDROCLORIDE

>A>		+	BIOVAIL	50MG	N21693	001	May 05, 2005	May	NEWA

TRETINOIN

>D> CREAM, AUGMENTED; TOPICAL
>D> RENOVA

>D>		+	JOHNSON AND JOHNSON	0.05%	N19963	001	Dec 29, 1995	May	CDFR

>A>		CREAM; TOPICAL							
>A>		RENOVA							
>A>	+	JOHNSON AND JOHNSON	0.05%	N19963	001	Dec 29, 1995	May	CDFR	
		SOLUTION; TOPICAL							
		TRETINOIN							
	AT	TEVA PHARMS	0.05%	N74873	001	Jun 19, 1998	Mar	CAHN	
		TRICHLORMETHIAZIDE							
		TABLET; ORAL							
		NAQUA							
		@ SCHERING	2MG	N12265	001		Feb	DISC	
		@	4MG	N12265	002		Feb	DISC	
		TRICHLORMETHIAZIDE							
		@ ABC HOLDING	4MG	N85568	001		Feb	DISC	
		@ PAR PHARM	2MG	N87007	001		Feb	DISC	
		@	4MG	N87005	001		Feb	DISC	
		TRIMETHOPRIM HYDROCHLORIDE							
		SOLUTION; ORAL							
		PRIMSOL							
		@ TARO PHARMS NORTH	EQ 25MG BASE/5ML	N74374	001	Jun 23, 1995	Jan	CAHN	
	+		EQ 50MG BASE/5ML	N74973	001	Jan 24, 2000	Jan	CAHN	
		URSODIOL							
		CAPSULE; ORAL							
		URSODIOL							
	AB	TEVA PHARMS	300MG	N75592	001	May 25, 2000	Mar	CAHN	
		VALPROIC ACID							
		SYRUP; ORAL							
		VALPROIC ACID							
	AA	TEVA PHARMS	250MG/5ML	N73178	001	Aug 25, 1992	Mar	CAHN	
		VERAPAMIL HYDROCHLORIDE							
		CAPSULE, EXTENDED RELEASE; ORAL							
		VERELAN PM							
>A>		ELAN DRUG	100MG	N20943	001	Nov 25, 1998	May	CAHN	
>A>			200MG	N20943	002	Nov 25, 1998	May	CAHN	
>A>	+		300MG	N20943	003	Nov 25, 1998	May	CAHN	
>D>		ELAN PHARM	100MG	N20943	001	Nov 25, 1998	May	CAHN	
			100MG	N20943	001	Nov 25, 1998	Mar	CRLD	
>D>			200MG	N20943	002	Nov 25, 1998	May	CAHN	
			200MG	N20943	002	Nov 25, 1998	Mar	CRLD	
>D>	+		300MG	N20943	003	Nov 25, 1998	May	CAHN	
		INJECTABLE; INJECTION							
		VERAPAMIL HCL							
>D>	AP	HOSPIRA	2.5MG/ML	N70739	001	May 06, 1987	May	DISC	
>A>		@	2.5MG/ML	N70739	001	May 06, 1987	May	DISC	
>D>	AP		2.5MG/ML	N70740	001	May 06, 1987	May	DISC	
>A>		@	2.5MG/ML	N70740	001	May 06, 1987	May	DISC	
		VINORELBINE TARTRATE							
		INJECTABLE; INJECTION							
		VINORELBINE TARTRATE							
	AP	AM PHARM	EQ 10MG BASE/ML	N76849	001	Apr 18, 2005	Mar	NEWA	
>A>	AP	MAYNE PHARMA USA	EQ 10MG BASE/ML	N76827	001	Jun 02, 2005	May	NEWA	

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

>D>	+ PFIZER	20MG	N20825	001	Feb 05, 2001	May	CPOT
>A>	+	EQ 20MG BASE	N20825	001	Feb 05, 2001	May	CPOT
>D>		40MG	N20825	002	Feb 05, 2001	May	CPOT
>A>		EQ 40MG BASE	N20825	002	Feb 05, 2001	May	CPOT
>D>		60MG	N20825	003	Feb 05, 2001	May	CPOT
>A>		EQ 60MG BASE	N20825	003	Feb 05, 2001	May	CPOT
>D>		80MG	N20825	004	Feb 05, 2001	May	CPOT
>A>		EQ 80MG BASE	N20825	004	Feb 05, 2001	May	CPOT

ASPIRIN

TABLET; ORAL
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

	BAYER	500MG	N21317	001	Oct 18, 2001	Mar	CMFD

BENTOQUATAM

LOTION; TOPICAL
IVY BLOCK

+	STAND HOMEOPATH	5%	N20532	001	Aug 26, 1996	Apr	CAHN

CHLORHEXIDINE GLUCONATE

CLOTH; TOPICAL
CHLORHEXIDINE GLUCONATE

+	SAGE PRODS	2%	N21669	001	Apr 25, 2005	Apr	NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL
CHLORAPREP ONE-STEP FREPP

+	MEDI FLEX INC	2%;70%	N20832	001	Jul 14, 2000	Apr	CTNA

CHLORAPREP WITH TINT

+	MEDI FLEX INC	2%;70%	N20832	002	May 03, 2005	Apr	NEWA

CLOTRIMAZOLE

TABLET; VAGINAL
GYNIX

	TEVA PHARMS	100MG	N73249	001	Feb 13, 1998	Mar	CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
DELSYM

+	UCB	EQ 30MG HBR/5ML	N18658	001	Oct 08, 1982	Apr	CAHN

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE

	PERRIGO	10MG	N75400	001	Mar 18, 2005	Mar	NEWA
	WOCKHARDT	10MG	N77146	001	Mar 07, 2005	Feb	NEWA

IBUPROFEN

CAPSULE; ORAL
IBUPROFEN

>D>		BANNER PHARMACAPS	200MG	N21472	001	Oct 18, 2002	May	CRLD
>A>	+		200MG	N21472	001	Oct 18, 2002	May	CRLD

TABLET; ORAL
IBUPROFEN

>A>		PERRIGO R AND D	200MG	N77349	001	Jun 21, 2005	May	NEWA

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
IMODIUM A-D

+	MCNEIL	1MG/7.5ML	N19487	002	Jul 08, 2004	Apr	NEWA

LORATADINE

SYRUP; ORAL

CLARITIN HIVES RELIEF						
@ SCHERING	1MG/ML	N20641	003	Nov 19, 2003	Jan	DISC

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE 3						
TARO	4%	N76773	001	Mar 02, 2005	Feb	NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX						
@ WATSON LABS	EQ 2MG BASE	N76568	001	Jul 29, 2004	Apr	DISC
@	EQ 4MG BASE	N76569	002	Jul 29, 2004	Apr	DISC
NICOTINE POLACRILEX (MINT)						
WATSON LABS	EQ 2MG BASE	N76569	001	Jul 29, 2004	Apr	CTNA
	EQ 4MG BASE	N76568	002	Jul 29, 2004	Apr	CTNA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2005

NO MAY 2005 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MAY 2005 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR								
021205 001	**>A>**	4724232	Sep 17, 2005			U-248		
	>A>	4818538	Sep 17, 2005		DP			
	>A>	4828838	Sep 17, 2005		DP			
	>A>	4833130	Sep 17, 2005			U-248		
	>A>	4837208	Sep 17, 2005			U-248		
	>A>	5034394	Jun 26, 2009	DS	DP			
	>A>	5034394*PED	Dec 26, 2009					
	>A>	5047407	Nov 17, 2009	DS	DP	U-248		
	>A>	5047407*PED	May 17, 2010					
	>A>	5905082	May 18, 2016	DS	DP	U-248		
	>A>	5905082*PED	Nov 18, 2016					
	>A>	6180639	Jan 30, 2018		DP	U-248		
	>A>	6180639*PED	Jul 30, 2018			U-248		
	>A>	6294540	May 14, 2018	DS	DP	U-65		
	>A>	6294540*PED	Nov 14, 2018			U-65		
	>A>	6417191	Mar 28, 2016		DP	U-248		
ALBUTEROL SULFATE - ALBUTEROL SULFATE HFA								
021457 001		5605674	Feb 25, 2014		DP			
		5695743	Jul 06, 2010		DP	U-491		
		5766573	Nov 28, 2009			U-356		
		6352684	Nov 28, 2009		DP			
ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D								
021762 001	**>A>**	4621077	Aug 06, 2007			U-648		
	>A>	4621077*PED	Feb 06, 2008					
	>A>	5358941	Dec 02, 2012		DP			
	>A>	5358941*PED	Jun 02, 2013					
	>A>	5681590	Dec 02, 2012		DP			
	>A>	5681590*PED	Jun 02, 2013					
	>A>	5994329	Jul 17, 2018			U-647		
	>A>	5994329*PED	Jan 17, 2019					
	>A>	6090410	Dec 02, 2012		DP			
	>A>	6090410*PED	Jun 02, 2013		DP			
ALPRAZOLAM - NIRAVAM								
021726 001		6024981	Apr 09, 2018		DP			
		6221392	Apr 09, 2018		DP			
ALPRAZOLAM - NIRAVAM								
021726 002		6024981	Apr 09, 2018		DP			
		6221392	Apr 09, 2018		DP			
ALPRAZOLAM - NIRAVAM								
021726 003		6024981	Apr 09, 2018		DP			
		6221392	Apr 09, 2018		DP			
ALPRAZOLAM - NIRAVAM								
021726 004		6024981	Apr 09, 2018		DP			
		6221392	Apr 09, 2018		DP			
ALPRAZOLAM - XANAX								
018276 004	**>A>**	5061494	Dec 12, 2008					
ARIPIPRAZOLE - ABILIFY								
021713 001							I-437	Sep 29, 2007
							I-401	Aug 28, 2006
							NCE	Nov 15, 2007
ARSENIC TRIOXIDE - TRISENOX								
021248 001		6855339	Nov 10, 2018			U-617		
		6861076	Nov 10, 2018			U-617		
	>A>	6884439	Nov 10, 2018			U-651		
ATOMOXETINE HYDROCHLORIDE - STRATTERA								
021411 007		5658590	Jan 11, 2015			U-494	NCE	Nov 26, 2007
		5658590*PED	Jul 11, 2015				PED	May 26, 2008
ATOMOXETINE HYDROCHLORIDE - STRATTERA								
021411 008		5658590	Jan 11, 2015			U-494	NCE	Nov 26, 2007
		5658590*PED	Jul 11, 2015				PED	May 26, 2008
BEXAROTENE - TARGRETIN								
021055 001		6043279	Apr 22, 2012			U-509		
		6320074	Apr 22, 2012	DS		U-509		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEXAROTENE - TARGRETIN						
021056 001	6043279	Apr 22, 2012		U-510		
	6320074	Apr 22, 2012	DS	U-510		
BORTEZOMIB - VELCADE						
021602 001					I-452	Mar 25, 2008
BROMFENAC SODIUM - XIBROM						
021664 001					NP	Mar 24, 2008
BUDESONIDE - ENTOCORT EC						
021324 001	>A> 6423340	Nov 15, 2010			I-454	Apr 29, 2008
	>A> 6423340*PED	May 11, 2011				
CANDESARTAN CILEXETIL - ATACAND						
020838 001					>A> I-456	May 18, 2008
					>A> I-455	May 18, 2008
					I-448	Feb 22, 2008
CANDESARTAN CILEXETIL - ATACAND						
020838 002					>A> I-456	May 18, 2008
					>A> I-455	May 18, 2008
					I-448	Feb 22, 2008
CANDESARTAN CILEXETIL - ATACAND						
020838 003					>A> I-456	May 18, 2008
					>A> I-455	May 18, 2008
					I-448	Feb 22, 2008
CANDESARTAN CILEXETIL - ATACAND						
020838 004					>A> I-456	May 18, 2008
					>A> I-455	May 18, 2008
					I-448	Feb 22, 2008
CARBAMAZEPINE - CARBATROL						
020712 003	5326570	Jul 05, 2011		U-215		
	5912013	Jun 15, 2016		U-277		
CARBAMAZEPINE - EQUETRO						
021710 001	5326570	Jul 23, 2011		DP U-627		
	5912013	Jun 15, 2016		DP		
CARBAMAZEPINE - EQUETRO						
021710 002	5326570	Jul 23, 2011		DP U-627		
	5912013	Jun 15, 2016		DP		
CARBAMAZEPINE - EQUETRO						
021710 003	5326570	Jul 23, 2011		DP U-627		
	5912013	Jun 15, 2016		DP		
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100						
021485 002	5446194	Oct 19, 2013	DS			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150						
021485 003	5446194	Oct 19, 2013	DS			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50						
021485 001	5446194	Oct 19, 2013	DS			
CETRORELIX - CETROTIDE						
021197 001	6863891	Feb 19, 2013		U-426		
CETRORELIX - CETROTIDE						
021197 002	6863891	Feb 19, 2013		U-426		
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE						
021669 001					>A> NDF	Apr 25, 2008
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP						
020832 001	>A> 5538353	Aug 25, 2015		DP		
	>A> 5690958	Sep 30, 2016		DP		
	>A> 5752363	Apr 22, 2017		DP		
	>A> 5772346	Apr 22, 2017		DP		
	>A> 6536975	Nov 10, 2020		DP		
	>A> D386849	Nov 25, 2011		DP		
	>A> D396911	Aug 11, 2012		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT					
020832 002	>A> 5538353	Aug 25, 2015	DP	NP	May 03, 2008
	>A> 5690958	Sep 30, 2016	DP		
	>A> 6536975	Nov 10, 2020	DP		
	>A> 6729786	Mar 14, 2023	DP		
CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR					
021744 001				>A> NDF	May 19, 2008
CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC					
020805 001	4844902	Feb 11, 2008	DP		
	5843930	Jul 06, 2015	U-646		
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR					
021473 001				>A> NC	Dec 13, 2005
				>A> PED	Jun 13, 2006
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR					
021473 002				>A> NC	Dec 13, 2005
				>A> PED	Jun 13, 2006
CLOFARABINE - CLOLAR					
021673 001	4918179	Jun 14, 2005	DS		
	5384310	May 23, 2009	DS DP		
	5661136	Aug 26, 2014	U-626		
COLESTIPOL HYDROCHLORIDE - COLESTID					
020222 001	5490987	Feb 13, 2013	DP		
DAPTOMYCIN - CUBICIN					
021572 001	6852689	Sep 24, 2019	U-282		
DAPTOMYCIN - CUBICIN					
021572 002	6852689	Sep 24, 2019	U-282		
DARIFENACIN HYDROBROMIDE - ENABLEX					
021513 001	5096890	Mar 13, 2010	DS DP U-631		
	6106864	Aug 21, 2016	DP U-630		
DARIFENACIN HYDROBROMIDE - ENABLEX					
021513 002	5096890	Mar 13, 2010	DS DP U-631		
	6106864	Aug 21, 2016	DP U-630		
DELAVIRDINE MESYLATE - RESCRIPTOR					
020705 002	>A> 6177101	Jun 07, 2019			
DESIRUDIN RECOMBINANT - IPRIVASK					
021271 001				NCE	Apr 04, 2008
DESLORATADINE - CLARINEX					
021165 001	4659716	Apr 21, 2006	U-427		
	4659716*PED	Oct 21, 2006	U-427		
DESLORATADINE - CLARINEX					
021300 001	4659716	Apr 21, 2006	DP U-611		
	4659716*PED	Oct 21, 2006			
DESLORATADINE - CLARINEX					
021312 001	4659716	Apr 21, 2006	U-427		
	4659716*PED	Oct 21, 2006	U-427		
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR					
021605 001	4659716	Apr 21, 2006	DP U-644	NCE	Dec 21, 2006
	4659716*PED	Oct 21, 2006		NC	Mar 03, 2008
	6100274	Jul 07, 2019	DP	PED	Jun 21, 2007
	6100274*PED	Jan 07, 2020			
DEXRAZOXANE HYDROCHLORIDE - DEXRAZOXANE					
076068 001				PC	Aug 27, 2005
DEXRAZOXANE HYDROCHLORIDE - DEXRAZOXANE					
076068 002				PC	Oct 19, 2005
DEXTROMETHORPHAN POLISTIREX - DELSYM					
018658 001	5980882	Apr 16, 2017	DP		
DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC					
020607 001	>A> 5698225	May 03, 2010	U-392		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC								
020607 002	**>A>**	5698225	May 03, 2010			U-392		
DIVALPROEX SODIUM - DEPAKOTE ER								
021168 001		6720004	Dec 18, 2018		DP			
DIVALPROEX SODIUM - DEPAKOTE ER								
021168 002		6720004	Dec 18, 2018		DP			
DOFETILIDE - TIKOSYN								
020931 001	**>A>**	4959366	Sep 25, 2012	DS	DP	U-652		
DOFETILIDE - TIKOSYN								
020931 002	**>A>**	4959366	Sep 25, 2012	DS	DP	U-652		
DOFETILIDE - TIKOSYN								
020931 003	**>A>**	4959366	Sep 25, 2012	DS	DP	U-652		
DOXAZOSIN MESYLATE - CARDURA XL								
021269 001							NDF	Feb 22, 2008
DOXAZOSIN MESYLATE - CARDURA XL								
021269 002		4837111	Mar 21, 2008		DP		NDF	Feb 22, 2008
DOXERCALCIFEROL - HECTOROL								
020862 001	**>A>**	6903083	Jul 18, 2021	DS	DP			
DOXERCALCIFEROL - HECTOROL								
020862 002	**>A>**	6903083	Jul 18, 2021	DS	DP			
DOXERCALCIFEROL - HECTOROL								
021027 001	**>A>**	6903083	Jul 18, 2021	DS	DP			
ENOXAPARIN SODIUM - LOVENOX								
020164 001	**>A>**	RE38743	Feb 14, 2012	DS	DP	U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 002	**>A>**	RE38743	Feb 14, 2012	DS	DP	U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 003	**>A>**	RE38743	Feb 14, 2012	DS	DP	U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 004	**>A>**	RE38743	Feb 14, 2012	DS	DP	U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 005	**>A>**	RE38743	Feb 14, 2012	DS	DP	U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 006	**>A>**	RE38743	Feb 14, 2012	DS	DP	U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 007	**>A>**	RE38743	Feb 14, 2012	DS	DP	U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 008	**>A>**	RE38743	Feb 14, 2012	DS	DP	U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 009	**>A>**	RE38743	Feb 14, 2012	DS	DP	U-545		
ENTACAPONE - COMTAN								
020796 001		5446194	Oct 19, 2013	DS				
ENTECAVIR - BARACLUDE								
021797 001		5206244	Oct 18, 2010	DS			NCE	Mar 29, 2010
ENTECAVIR - BARACLUDE								
021797 002		5206244	Oct 18, 2010	DS			NCE	Mar 29, 2010
ENTECAVIR - BARACLUDE								
021798 001		5206244	Oct 18, 2010	DS			NCE	Mar 29, 2010
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT								
021504 001		6862473	Sep 30, 2013		DP			
EPLERENONE - INSPRA								
021437 001		4559332	Apr 09, 2006	DS	DP	U-537		
EPLERENONE - INSPRA								
021437 002		4559332	Apr 09, 2006	DS	DP	U-537		
EPLERENONE - INSPRA								
021437 003		4559332	Apr 09, 2006	DS	DP	U-537		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERTAPENEM SODIUM - INVANZ					
021337 001	5478820	Feb 02, 2013		NCE	Nov 21, 2006
	5478820*PED	Aug 02, 2013		PED	May 21, 2007
	5652233	Feb 02, 2013			
	5652233*PED	Aug 02, 2013			
	5952323	May 15, 2017			
	5952323*PED	Nov 15, 2017			
ESMOLOL HYDROCHLORIDE - ESMOLOL HCL					
076323 001				PC	May 01, 2005
ESOMEPRAZOLE MAGNESIUM - NEXIUM					
021153 001	4738974	Apr 19, 2006	DS DP U-635		
	4738974	Apr 19, 2006	DS DP U-373		
	4738974*PED	Oct 19, 2006	U-373		
	6875872	May 27, 2014	DS		
	6875872*PED	Nov 27, 2014			
ESOMEPRAZOLE MAGNESIUM - NEXIUM					
021153 002	4738974	Apr 19, 2006	DS DP U-635		
	4738974	Apr 19, 2006	DS DP U-373		
	4738974*PED	Oct 19, 2006	U-373		
	6875872	May 27, 2014	DS		
	6875872*PED	Nov 27, 2014			
ESOMEPRAZOLE SODIUM - NEXIUM IV					
021689 001	5877192	May 27, 2014	U-643	NE	Mar 31, 2008
	5877192*PED	Nov 27, 2014			
	6143771	May 27, 2014	DP U-643		
ESOMEPRAZOLE SODIUM - NEXIUM IV					
021689 002	5877192	May 27, 2014	U-643	NE	Mar 31, 2008
	5877192*PED	Nov 27, 2014			
	6143771	May 27, 2014	DP U-643		
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA					
021443 001	6660726	Mar 08, 2021	DS DP U-284	NP	Dec 20, 2007
	6660726	Mar 08, 2021	DS DP U-196		
	6855703	Feb 12, 2021	DS DP U-284		
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA					
021443 002	6660726	Mar 08, 2021	DS DP U-284	NP	Dec 20, 2007
	6660726	Mar 08, 2021	DS DP U-196		
	6855703	Feb 12, 2021	DS DP U-284		
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA					
021443 003	6660726	Mar 08, 2021	DS DP U-284		
	6660726	Mar 08, 2021	DS DP U-196		
	6855703	Feb 12, 2021	DS DP U-284		
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA					
021443 004	6660726	Mar 08, 2021	DS DP U-284		
	6660726	Mar 08, 2021	DS DP U-196		
	6855703	Feb 12, 2021	DS DP U-284		
ESZOPICLONE - LUNESTA					
021476 001	6319926	Jan 16, 2012	U-620		
	6444673	Jan 16, 2012	DS DP		
	6864257	Aug 30, 2012	U-629		
ESZOPICLONE - LUNESTA					
021476 002	6319926	Jan 16, 2012	U-620		
	6444673	Jan 16, 2012	DS DP		
	6864257	Aug 30, 2012	U-629		
ESZOPICLONE - LUNESTA					
021476 003	6319926	Jan 16, 2012	U-620		
	6444673	Jan 16, 2012	DS DP		
	6864257	Aug 30, 2012	U-629		
ETHINYL ESTRADIOL; NORGESTIMATE - ORTHO CYCLEN-21					
019653 001				**>A>** M-41	May 13, 2008
				>A> PED	Nov 13, 2008
ETHINYL ESTRADIOL; NORGESTIMATE - ORTHO CYCLEN-28					
019653 002				**>A>** M-41	May 13, 2008
				>A> PED	Nov 13, 2008

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETHINYL ESTRADIOL; NORGESTIMATE - ORTHO TRI-CYCLEN								
019697 001							>A> M-41	May 13, 2008
							>A> PED	Nov 13, 2008
ETHINYL ESTRADIOL; NORGESTIMATE - ORTHO TRI-CYCLEN								
019697 002							>A> M-41	May 13, 2008
							>A> PED	Nov 13, 2008
EXEMESTANE - AROMASIN								
020753 001	>A>	4808616	Apr 01, 2011	DS	DP	U-658		
EXENATIDE SYNTHETIC - BYETTA								
021773 001	>A>	5424286	May 24, 2013			U-653	NCE	Apr 28, 2010
	>A>	6858576	Jan 06, 2017			U-656		
	>A>	6872700	Jan 14, 2020			U-654		
EXENATIDE SYNTHETIC - BYETTA								
021773 002	>A>	5424286	May 24, 2013			U-653	NCE	Apr 28, 2010
	>A>	6858576	Jan 06, 2017			U-656		
	>A>	6872700	Jan 14, 2020			U-654		
FAMOTIDINE - FLUXID								
021712 001		6024981	Apr 09, 2018		DP			
		6221392	Apr 09, 2018		DP			
FAMOTIDINE - FLUXID								
021712 002		6024981	Apr 09, 2018		DP			
		6221392	Apr 09, 2018		DP			
FENTANYL - DURAGESIC-12								
019813 005							NPP	May 20, 2006
							PED	Nov 20, 2006
FENTANYL CITRATE - ACTIQ								
020747 001		5785989	May 01, 2005					
FENTANYL CITRATE - ACTIQ								
020747 002		5785989	May 01, 2005					
FENTANYL CITRATE - ACTIQ								
020747 003		5785989	May 01, 2005					
FENTANYL CITRATE - ACTIQ								
020747 004		5785989	May 01, 2005					
FENTANYL CITRATE - ACTIQ								
020747 005		5785989	May 01, 2005					
FENTANYL CITRATE - ACTIQ								
020747 006		5785989	May 01, 2005					
FLUOCINOLONE ACETONIDE - RETISERT								
021737 001							NDF	Apr 08, 2008
FLUOCINONIDE - VANOS								
021758 001	>A>	6765001	Dec 21, 2021		DP		NP	Feb 11, 2008
FLUTICASONE PROPIONATE - CUTIVATE								
021152 001							NDF	Mar 31, 2008
							PED	Sep 30, 2008
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50								
021077 001		6536427	Mar 01, 2011		DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50								
021077 002		6536427	Mar 01, 2011		DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50								
021077 003		6536427	Mar 01, 2011		DP			
FONDAPARINUX SODIUM - ARIXTRA								
021345 001							>A> I-457	May 26, 2008
FONDAPARINUX SODIUM - ARIXTRA								
021345 002							>A> I-457	May 26, 2008
FONDAPARINUX SODIUM - ARIXTRA								
021345 003							>A> I-457	May 26, 2008
FONDAPARINUX SODIUM - ARIXTRA								
021345 004							>A> I-457	May 26, 2008

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GALANTAMINE HYDROBROMIDE - REMINYL								
021169 001		6358527	Jun 06, 2017		DP	U-322		
GALANTAMINE HYDROBROMIDE - REMINYL								
021169 002		6358527	Jun 06, 2017		DP	U-322		
GALANTAMINE HYDROBROMIDE - REMINYL								
021169 003		6358527	Jun 06, 2017		DP	U-322		
GALANTAMINE HYDROBROMIDE - REMINYL								
021615 001	**>A>**	4663318	Dec 14, 2008			U-322		
GALANTAMINE HYDROBROMIDE - REMINYL								
021615 002	**>A>**	4663318	Dec 14, 2008			U-322		
GALANTAMINE HYDROBROMIDE - REMINYL								
021615 003	**>A>**	4663318	Dec 14, 2008			U-322		
GEMCITABINE HYDROCHLORIDE - GEMZAR								
020509 001		4808614	May 15, 2010	DS			I-428	May 19, 2007
		4808614*PED	Nov 15, 2010				M-40	Apr 26, 2008
		5464826	Nov 07, 2012			U-146	PED	Oct 26, 2008
		5464826*PED	May 07, 2013				PED	Nov 19, 2007
GEMCITABINE HYDROCHLORIDE - GEMZAR								
020509 002		4808614	May 15, 2010	DS			I-428	May 19, 2007
		4808614*PED	Nov 15, 2010				M-40	Apr 26, 2008
		5464826	Nov 07, 2012			U-146	PED	Oct 26, 2008
		5464826*PED	May 07, 2013				PED	Nov 19, 2007
GLIPIZIDE - GLUCOTROL XL								
020329 001	**>A>**	5545413	Jul 02, 2008			U-111		
GLIPIZIDE - GLUCOTROL XL								
020329 002	**>A>**	5545413	Jul 02, 2008			U-111		
GLIPIZIDE - GLUCOTROL XL								
020329 003	**>A>**	5545413	Jul 02, 2008			U-111		
GLYBURIDE - GLYNASE								
020051 001	**>A>**	4735805	Mar 11, 2007					
GLYBURIDE - GLYNASE								
020051 002	**>A>**	4735805	Mar 11, 2007					
GLYBURIDE - GLYNASE								
020051 003	**>A>**	4735805	Mar 11, 2007					
GLYBURIDE - GLYNASE								
020051 004	**>A>**	4735805	Mar 11, 2007					
GRANISETRON HYDROCHLORIDE - KYTRIL								
020239 003		4886808	Dec 29, 2007	DS	DP	U-89	I-369	Aug 16, 2005
GRANISETRON HYDROCHLORIDE - KYTRIL								
020239 004							I-369	Aug 16, 2005
HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE								
020758 004		5270317	Sep 30, 2011	DS	DP			
		5270317*PED	Mar 30, 2012					
		5994348	Jun 07, 2015		DP			
		5994348*PED	Dec 07, 2015					
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR								
020387 001		5138069	Aug 11, 2009	DS				
	>A>	5153197	Oct 06, 2009		DP	U-3		
	>A>	5153197	Oct 06, 2009		DP	U-538		
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR								
020387 002		5138069	Aug 11, 2009	DS				
	>A>	5153197	Oct 06, 2009		DP	U-3		
	>A>	5153197	Oct 06, 2009		DP	U-538		
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT								
021532 002		6878703	Nov 19, 2021			U-3		
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT								
021532 003		6878703	Nov 19, 2021			U-3		
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT								
021532 005		6878703	Nov 19, 2021			U-3		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)		EXCLUSIVITY EXPIRATION DATE
IBANDRONATE SODIUM - BONIVA									
021455 002		4927814	Jul 09, 2007	DS	DP	U-642	D-96		Mar 24, 2008
		6294196	Oct 07, 2019		DP		NS		Mar 24, 2008
							NCE		May 16, 2008
IMATINIB MESYLATE - GLEEVEC									
021335 001		5521184	Jan 04, 2015						
	>A>	6894051	May 23, 2019	DS	DP	U-649			
IMATINIB MESYLATE - GLEEVEC									
021335 002		5521184	Jan 04, 2015						
	>A>	6894051	May 23, 2019	DS	DP	U-649			
IMATINIB MESYLATE - GLEEVEC									
021588 001		5521184	Jan 04, 2015						
	>A>	6894051	May 23, 2019	DS	DP	U-649			
IMATINIB MESYLATE - GLEEVEC									
021588 002		5521184	Jan 04, 2015						
	>A>	6894051	May 23, 2019	DS	DP	U-649			
INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30									
021172 001	**>A>**	5618913	Apr 08, 2014						
	>A>	5618913*PED	Oct 08, 2014						
INSULIN ASPART RECOMBINANT - NOVOLOG									
020986 001	**>A>**	5618913	Apr 08, 2014				**>A>** NCE		Jun 07, 2005
	>A>	5618913*PED	Oct 08, 2014				**>A>** PED		Dec 07, 2005
	>A>	5866538	Jun 20, 2017						
	>A>	5866538*PED	Dec 20, 2017						
ITRACONAZOLE - ITRACONAZOLE									
076104 001							PC		Aug 08, 2005
LANSOPRAZOLE - PREVACID									
021428 001	**>A>**	6328994	May 17, 2019						
LANSOPRAZOLE - PREVACID									
021428 002	**>A>**	6328994	May 17, 2019						
LETROZOLE - FEMARA									
020726 001							I-446		Oct 29, 2007
LEUPROLIDE ACETATE - ELIGARD									
021731 001		4938763	Oct 03, 2008		DP	U-621			
		5278201	Jan 11, 2011		DP				
		5324519	Jun 28, 2011		DP				
		5599552	Feb 04, 2014		DP	U-621			
		5739176	Oct 03, 2008		DP	U-621			
		6395293	Sep 28, 2013		DP				
		6565874	Oct 28, 2018		DP	U-621			
		6626870	Mar 27, 2020		DP				
		6773714	Oct 28, 2018			U-621			
		RE37950	Oct 03, 2008		DP	U-621			
LEVALBUTEROL TARTRATE - XOPENEX HFA									
021730 001		5225183	Jul 06, 2010		DP		NP		Mar 11, 2008
		5362755	Nov 08, 2011			U-636			
		5439670	Jul 06, 2010		DP				
		5547994	Aug 20, 2013			U-636			
		5605674	Feb 25, 2014		DP				
		5695743	Jul 06, 2010		DP	U-636			
		5760090	Jan 05, 2010			U-636			
		5836299	Nov 17, 2017		DP				
		5844002	Jan 05, 2010			U-636			
		6083993	Jan 05, 2010			U-636			
		6352684	Nov 28, 2009		DP				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINEZOLID - ZYVOX					
021130 001	5688792	Nov 18, 2014	DS	U-319 I-431	Jun 23, 2007
	5688792*PED	May 18, 2015		I-402	Jul 22, 2006
	6514529	Mar 15, 2021	DP	NPP	Dec 19, 2005
	6514529*PED	Sep 15, 2021		NCE	Apr 18, 2005
	6559305	Jan 29, 2021	DS	PED	Dec 23, 2007
	6559305*PED	Jul 29, 2021		PED	Jan 22, 2007
				PED	Jun 19, 2006
				PED	Oct 18, 2005
LINEZOLID - ZYVOX					
021130 002	5688792	Nov 18, 2014	DS	U-319 I-431	Jun 23, 2007
	5688792*PED	May 18, 2015		I-402	Jul 22, 2006
	6514529	Mar 15, 2021	DP	NPP	Dec 19, 2005
	6514529*PED	Sep 15, 2021		NCE	Apr 18, 2005
	6559305	Jan 29, 2021	DS	PED	Dec 23, 2007
	6559305*PED	Jul 29, 2021		PED	Jan 22, 2007
				PED	Jun 19, 2006
				PED	Oct 18, 2005
LINEZOLID - ZYVOX					
021131 001	5688792	Nov 18, 2014		U-319 I-431	Jun 23, 2007
	5688792*PED	May 18, 2015		I-402	Jul 22, 2006
	6559305	Jan 29, 2021	DS	NPP	Dec 19, 2005
	6559305*PED	Jul 29, 2021		NCE	Apr 18, 2005
				PED	Dec 23, 2007
				PED	Jan 22, 2007
				PED	Jun 19, 2006
				PED	Oct 18, 2005
LINEZOLID - ZYVOX					
021132 001	5688792	Nov 18, 2014	DS	U-319 I-431	Jun 23, 2007
	5688792*PED	May 18, 2015		I-402	Jul 22, 2006
	6559305	Jan 29, 2021	DS	NPP	Dec 19, 2005
	6559305*PED	Jul 29, 2021		NCE	Apr 18, 2005
				PED	Dec 23, 2007
				PED	Jan 22, 2007
				PED	Jun 19, 2006
				PED	Oct 18, 2005
LOPINAVIR; RITONAVIR - KALETRA					
021226 001				>A> D-99	Apr 29, 2008
LOPINAVIR; RITONAVIR - KALETRA					
021251 001				>A> D-99	Apr 29, 2008
LOVASTATIN - ALTOPREV					
021316 001	6485748	Dec 12, 2017	DP		
LOVASTATIN - ALTOPREV					
021316 002	6485748	Dec 12, 2017	DP		
LOVASTATIN - ALTOPREV					
021316 003	6485748	Dec 12, 2017	DP		
LOVASTATIN - ALTOPREV					
021316 004	6485748	Dec 12, 2017	DP		
MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104					
021583 001	6495534	May 15, 2020	DP	I-451	Mar 25, 2008
MELOXICAM - MOBIC					
020938 001				I-430	Jul 16, 2007
				NCE	Apr 13, 2005
				PED	Jan 16, 2008
				PED	Oct 13, 2005
MELOXICAM - MOBIC					
020938 002				>A> I-430	Jul 16, 2007
				>A> NCE	Apr 13, 2005
				>A> PED	Jan 16, 2008
				>A> PED	Oct 13, 2005

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MELOXICAM - MOBIC								
021530 001		6184220	Mar 25, 2019		DP		I-430	Jul 16, 2007
		6184220*PED	Sep 25, 2019				NCE	Apr 13, 2005
							PED	Jan 16, 2008
							PED	Oct 13, 2005
MEMANTINE HYDROCHLORIDE - NAMENDA								
021627 001							>A> NCE	Oct 16, 2008
METFORMIN HYDROCHLORIDE - FORTAMET								
021574 001		6866866	Mar 17, 2021		DP			
METFORMIN HYDROCHLORIDE - FORTAMET								
021574 002		6866866	Mar 17, 2021		DP			
METFORMIN HYDROCHLORIDE - METFORMIN HCL								
076863 001							PC	Apr 12, 2005
METFORMIN HYDROCHLORIDE - RIOMET								
021591 001	>A>	6890957	Sep 14, 2023		DP			
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
021284 001	>A>	6228398	Nov 01, 2019		DP	U-472		
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
021284 002	>A>	6228398	Nov 01, 2019		DP	U-472		
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
021284 003	>A>	6228398	Nov 01, 2019		DP	U-472		
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
021284 004	>A>	6228398	Nov 01, 2019		DP			
METOPROLOL SUCCINATE - TOPROL-XL								
019962 001		4927640	May 22, 2007		DP		D-95	Feb 15, 2008
		4957745	Sep 18, 2007		DP	U-107		
		5001161	Sep 18, 2007		DP			
		5081154	Sep 18, 2007	DS				
METOPROLOL SUCCINATE - TOPROL-XL								
019962 002		4927640	May 22, 2007		DP		D-95	Feb 15, 2008
		4957745	Sep 18, 2007		DP	U-107		
		5001161	Sep 18, 2007		DP			
		5081154	Sep 18, 2007	DS				
METOPROLOL SUCCINATE - TOPROL-XL								
019962 003		4927640	May 22, 2007		DP		D-95	Feb 15, 2008
		4957745	Sep 18, 2007		DP	U-107		
		5001161	Sep 18, 2007		DP			
		5081154	Sep 18, 2007	DS				
METOPROLOL SUCCINATE - TOPROL-XL								
019962 004		4927640	May 22, 2007		DP		D-95	Feb 15, 2008
		4957745	Sep 18, 2007		DP	U-107		
		5001161	Sep 18, 2007		DP	U-107		
		5081154	Sep 18, 2007	DS		U-107		
MICAFUNGIN SODIUM - MYCAMINE								
021506 002	>A>	5376634	Dec 27, 2011	DS	DP		NCE	Mar 16, 2010
	>A>	6107458	Sep 29, 2015	DS	DP	U-650		
	>A>	6265536	Sep 29, 2015	DS	DP	U-650		
	>A>	6774104	Jan 08, 2021		DP	U-650		
MODAFINIL - PROVIGIL								
020717 001							I-449	Jan 23, 2007
MODAFINIL - PROVIGIL								
020717 002							I-449	Jan 23, 2007

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MOMETASONE FUROATE - ASMANEX TWISTHALER							
021067 001	5394868	Jun 25, 2012		DP		NP	Mar 30, 2008
	5687710	Nov 18, 2014		DP			
	5829434	Nov 03, 2015		DP			
	5889015	Jan 27, 2014			U-645		
	6057307	Jan 27, 2014		DP	U-645		
	6240918	Feb 20, 2017		DP			
	6365581	Jan 27, 2014			U-645		
	6503537	Mar 17, 2018		DP			
	6677322	Jan 27, 2014			U-645		
MOMETASONE FUROATE - MOMETASONE FUROATE							
077180 001						**>A>** PC	Nov 19, 2005
MOMETASONE FUROATE MONOHYDRATE - NASONEX							
020762 001	5837699	Jan 27, 2014		DP	U-625		
	6127353	Oct 03, 2017	DS	DP			
	6723713	Jan 27, 2014			U-625		
NATEGLINIDE - STARLIX							
021204 001	6844008	Nov 14, 2017		DP	U-214		
	RE34878	Sep 08, 2009					
NATEGLINIDE - STARLIX							
021204 002	6844008	Nov 14, 2017		DP	U-214		
	RE34878	Sep 08, 2009					
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)							
076313 001						PC	Oct 02, 2005
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)							
076313 002						PC	Oct 02, 2005
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)							
076313 003						PC	Oct 02, 2005
OCTREOTIDE ACETATE - SANDOSTATIN							
019667 005	5753618	Jul 08, 2008					
OLMESARTAN MEDOXOMIL - BENICAR							
021286 001	6878703	Nov 19, 2021			U-3		
OLMESARTAN MEDOXOMIL - BENICAR							
021286 003	6878703	Nov 19, 2021			U-3		
OLMESARTAN MEDOXOMIL - BENICAR							
021286 004	6878703	Nov 19, 2021			U-3		
OMEPRAZOLE - ZEGERID							
021706 001	5840737	Jul 16, 2016	DS		U-624		
	5840737	Jul 16, 2016	DS		U-623		
	6489346	Jul 16, 2016	DS	DP	U-624		
	6489346	Jul 16, 2016	DS	DP	U-623		
	6645988	Jul 16, 2016	DS	DP			
	6699885	Jul 16, 2016			U-624		
	6699885	Jul 16, 2016			U-623		
	6780882	Jul 16, 2016	DS	DP			
ONDANSETRON HYDROCHLORIDE - ZOFRAN							
020007 001						D-98	Mar 25, 2008
						D-97	Mar 25, 2008
						PED	Sep 25, 2008
						PED	Sep 25, 2008
ONDANSETRON HYDROCHLORIDE - ZOFRAN PRESERVATIVE FREE							
020007 003						D-98	Mar 25, 2008
						D-97	Mar 25, 2008
						PED	Sep 25, 2008
						PED	Sep 25, 2008
OXALIPLATIN - ELOXATIN							
021759 001						I-441	Nov 04, 2007
						NCE	Aug 09, 2007
OXALIPLATIN - ELOXATIN							
021759 002						I-441	Nov 04, 2007
						NCE	Aug 09, 2007

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXCARBAZEPINE - TRILEPTAL								
021014 001							NCE	Jan 14, 2005
							PED	Jul 14, 2005
OXCARBAZEPINE - TRILEPTAL								
021014 002							NCE	Jan 14, 2005
							PED	Jul 14, 2005
OXCARBAZEPINE - TRILEPTAL								
021014 003							NCE	Jan 14, 2005
							PED	Jul 14, 2005
OXCARBAZEPINE - TRILEPTAL								
021285 001							NCE	Jan 14, 2005
							PED	Jul 14, 2005
PACLITAXEL - ABRAXANE								
021660 001		5439686	Feb 22, 2013		DP		NP	Jan 07, 2008
		5498421	Mar 12, 2013		DP	U-634		
		6096331	Feb 22, 2013		DP	U-633		
		6506405	Feb 22, 2013		DP	U-633		
		6537579	Feb 22, 2013			U-632		
		6749868	Feb 22, 2013		DP			
		6753006	Feb 22, 2013		DP			
PARICALCITOL - ZEMPLAR								
021606 001							**>A>** NDF	May 26, 2008
PARICALCITOL - ZEMPLAR								
021606 002							**>A>** NDF	May 26, 2008
PARICALCITOL - ZEMPLAR								
021606 003							**>A>** NDF	May 26, 2008
PEGAPTANIB SODIUM - MACUGEN								
021756 001		5919455	Oct 27, 2013	DS				
		5932462	Aug 03, 2016	DS				
		6011020	Jan 04, 2017	DS				
	>A>	6051698	Oct 17, 2012	DS				
		6113906	Oct 27, 2013	DS				
		6147204	Jun 11, 2010	DS				
		6426335	Jun 11, 2010			U-622		
PRAMLINTIDE ACETATE - SYMLIN								
021332 001		5175145	Dec 29, 2009			U-637	NCE	Mar 16, 2010
		5686411	Nov 11, 2014	DS	DP	U-638		
		5814600	Sep 29, 2015			U-639		
		5998367	Mar 08, 2011	DS	DP			
		6114304	Sep 05, 2017			U-640		
		6410511	Jan 09, 2018		DP			
		6608029	Sep 07, 2013			U-641		
		6610824	Mar 08, 2011	DS				
PREGABALIN - LYRICA								
021446 001		6001876	Jul 16, 2017			U-55		
		6197819	Mar 06, 2018	DS	DP			
PREGABALIN - LYRICA								
021446 002		6001876	Jul 16, 2017			U-55		
		6197819	Mar 06, 2018	DS	DP			
PREGABALIN - LYRICA								
021446 003		6001876	Jul 16, 2017			U-55		
		6197819	Mar 06, 2018	DS	DP			
PREGABALIN - LYRICA								
021446 004		6001876	Jul 16, 2017			U-55		
		6197819	Mar 06, 2018	DS	DP			
PREGABALIN - LYRICA								
021446 005		6001876	Jul 16, 2017			U-55		
		6197819	Mar 06, 2018	DS	DP			
PREGABALIN - LYRICA								
021446 006		6001876	Jul 16, 2017			U-55		
		6197819	Mar 06, 2018	DS	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREGABALIN - LYRICA								
021446 007		6001876	Jul 16, 2017			U-55		
		6197819	Mar 06, 2018	DS	DP			
PREGABALIN - LYRICA								
021446 008		6001876	Jul 16, 2017			U-55		
		6197819	Mar 06, 2018	DS	DP			
RALOXIFENE HYDROCHLORIDE - EVISTA								
020815 001	**>A>**	6894064	Mar 10, 2017		DP	U-657		
RIBAVIRIN - COPEGUS								
021511 001							I-447	Feb 25, 2008
RISPERIDONE - RISPERDAL								
021444 004		4804663	Dec 29, 2007	DS	DP	U-543		
		5648093	Jul 15, 2014		DP			
		6224905	Jun 10, 2017		DP			
RISPERIDONE - RISPERDAL								
021444 005		4804663	Dec 29, 2007	DS	DP	U-543		
		5648093	Jul 15, 2014		DP			
		6224905	Jun 10, 2017		DP			
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 001	**>A>**	4452808	Dec 07, 2007	DS	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 002	**>A>**	4452808	Dec 07, 2007	DS	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 003	**>A>**	4452808	Dec 07, 2007	DS	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 004	**>A>**	4452808	Dec 07, 2007	DS	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 005	**>A>**	4452808	Dec 07, 2007	DS	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 006	**>A>**	4452808	Dec 07, 2007	DS	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 007	**>A>**	4452808	Dec 07, 2007	DS	DP			
ROSIGLITAZONE MALEATE - AVANDIA								
021071 002		5002953	Aug 30, 2008	DS	DP	U-628	I-453	Feb 28, 2008
		5002953	Aug 30, 2008	DS	DP	U-329		
		5741803	Apr 21, 2015	DS	DP	U-628		
		5741803	Apr 21, 2015	DS	DP	U-329		
ROSIGLITAZONE MALEATE - AVANDIA								
021071 003		5002953	Aug 30, 2008	DS	DP	U-628	I-453	Feb 28, 2008
		5002953	Aug 30, 2008	DS	DP	U-329		
		5741803	Apr 21, 2015	DS	DP	U-628		
		5741803	Apr 21, 2015	DS	DP	U-329		
ROSIGLITAZONE MALEATE - AVANDIA								
021071 004		5002953	Aug 30, 2008	DS	DP	U-628	I-453	Feb 28, 2008
		5002953	Aug 30, 2008	DS	DP	U-329		
		5741803	Apr 21, 2015	DS	DP	U-628		
		5741803	Apr 21, 2015	DS	DP	U-329		
ROSUVASTATIN CALCIUM - CRESTOR								
021366 002		6858618	Dec 17, 2021			U-618		
ROSUVASTATIN CALCIUM - CRESTOR								
021366 003		6858618	Dec 17, 2021			U-618		
ROSUVASTATIN CALCIUM - CRESTOR								
021366 004		6858618	Dec 17, 2021			U-618		
ROSUVASTATIN CALCIUM - CRESTOR								
021366 005		6858618	Dec 17, 2021			U-618		
SIROLIMUS - RAPAMUNE								
021083 001		5536729	Sep 30, 2013		DP		NPP	Mar 11, 2008
							PED	Sep 11, 2008

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIROLIMUS - RAPAMUNE							
021110 001	5989591	Mar 11, 2018		DP		NPP	Mar 11, 2008
						PED	Sep 11, 2008
SIROLIMUS - RAPAMUNE							
021110 002	5989591	Mar 11, 2018		DP		NPP	Mar 11, 2008
						PED	Sep 11, 2008
SIROLIMUS - RAPAMUNE							
021110 003	5100899	Jun 06, 2009			U-290	NPP	Mar 11, 2008
	5100899*PED	Dec 06, 2009				PED	Sep 11, 2008
	5212155	May 18, 2010			U-291		
	5212155*PED	Nov 18, 2010					
	5403833	Apr 04, 2012			U-293		
	5403833*PED	Oct 04, 2012					
	5989591	Mar 11, 2018		DP			
	5989591*PED	Sep 11, 2018					
SODIUM BENZOATE; SODIUM PHENYLACETATE - AMMONUL							
020645 001						NDF	Feb 17, 2008
						ODE	Feb 17, 2012
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 001	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 002	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 003	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 005	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 008	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 009	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 010	4968299	Jun 28, 2008		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 011	4968299	Jun 28, 2008		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 012	4968299	Jun 28, 2008		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 013	4968299	Jun 28, 2008		DP			
TELITHROMYCIN - KETEK							
021144 002	5635485	Apr 21, 2015	DS	DP	U-578	NCE	Apr 01, 2009
	D459798	Sep 24, 2015		DP			
TEMOZOLOMIDE - TEMODAR							
021029 001	5260291	Aug 11, 2013	DS	DP	U-619	I-450	Mar 15, 2008
	5260291*PED	Feb 11, 2014				ODE	Mar 15, 2012
TEMOZOLOMIDE - TEMODAR							
021029 002	5260291	Aug 11, 2013	DS	DP	U-619	I-450	Mar 15, 2008
	5260291*PED	Feb 11, 2014				ODE	Mar 15, 2012
TEMOZOLOMIDE - TEMODAR							
021029 003	5260291	Aug 11, 2013	DS	DP	U-619	I-450	Mar 15, 2008
	5260291*PED	Feb 11, 2014				ODE	Mar 15, 2012
TEMOZOLOMIDE - TEMODAR							
021029 004	5260291	Aug 11, 2013	DS	DP	U-619	I-450	Mar 15, 2008
	5260291*PED	Feb 11, 2014				ODE	Mar 15, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID					
020785 001	6869399	Oct 23, 2020	U-371		
THALIDOMIDE - THALOMID					
020785 002	6869399	Oct 23, 2020	U-371		
THALIDOMIDE - THALOMID					
020785 003	6869399	Oct 23, 2020	U-371		
TOPIRAMATE - TOPAMAX					
020505 001				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX					
020505 002				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX					
020505 003				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX					
020505 004				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX					
020505 005				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX					
020505 006				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX SPRINKLE					
020844 001				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX SPRINKLE					
020844 002				I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX SPRINKLE					
020844 003				I-41	Aug 11, 2007
VORICONAZOLE - VFEND					
021266 001	5567817	May 24, 2016 DS	DP U-540		
VORICONAZOLE - VFEND					
021266 002	5567817	May 24, 2016 DS	DP U-540		
VORICONAZOLE - VFEND					
021267 001	5567817	May 24, 2016 DS	DP U-540		
VORICONAZOLE - VFEND					
021630 001	5567817	May 24, 2016 DS	DP U-540		
ZICONOTIDE - PRIALT					
021060 001	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		
ZICONOTIDE - PRIALT					
021060 002	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		
ZICONOTIDE - PRIALT					
021060 003	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		
ZICONOTIDE - PRIALT					
021060 004	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE

Footnote:
1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
DS = Drug Substance claim
DP = Drug Product claim
U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of Patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm